DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –1– 
08/31/2016    
COVER PAGE  
     
DCP Protocol #:  MDA2016 -08-02 
 
Local Protocol #:  2017 -0911  
 
A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer  
 
 
Consortium Name:   University of Texas MD Anderson Early Phase Clinical Research 
Consortium  
Name of Consortium Principal  Powel H. Brown, MD, PhD  
Investigator:   Professor and Chair, Department of Clinical Cancer Prevention  
  University of Texas MD Anderson Cancer Center  
  1515 Holcombe Boulevard, Unit 1360  
Houston, TX 77030 -4009  
Telephone: (713) 792 -4509  
Fax: (713) 794 -4679  
  phbrown@mdanderson.org  
 
MD Anderson Consortium   Lana A. Vornik, MHA, MS  
Administrative Director:   Associate Director, Research Planning and Development  
  Department of Clinical Cancer Prevention  
  University of Texas MD Anderson Cancer Center  
  1515 Holcombe Boulevard, Unit 1360  
Houston, TX 77030 -4009  
Telephone: ( 713) 792-9594  
Fax: (713) 745 -4230  
  lavornik@mdanderson.org  
 
MD Anderson Consortium   Saba Abutaseh, BS  
Lead Org Coordinator:   CLO Coordinator  
  Department of Clinical Cancer Prevention  
  University of Texas MD Anderson Cancer Center  
  1515 Holcombe Boulevard, Unit 1360  
Houston, TX 77030 -4009  
Telephone: 713 -745-8181  
Fax: (713) 745 -4230  
  sgabutas @mdanderson.org  
 
 
Organization Name:    University of Texas MD Anderson Cancer Center   
Protocol Principal Investigator:  Parijatham Thomas, M.D.  
Assistant Professor  
Department of Clinical Cancer Prevention  
1515 Holcombe Blvd.  
Unit 1360  
Houston, TX   77030  
Telephone: (713) 745 -1075  
Fax: (713) 794-4403  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –2– 
08/31/2016   psthomas@mdanderson.org  
 
Organization Name:    University of Texas MD Anderson Cancer Center   
Co-Principal Investigator:  Anisha B. Patel, M.D.  
Assistant Professor  
Department of Dermatology  
1515 Holcombe Blvd.  
Unit 1452  
Houston, TX   77030  
Telephone: 713-745-4615  
APatel11 @mdanderson.org  
 
 
Organization:   University of Texas MD Anderson Cancer Center  
Lead Statistician:   J. Jack Lee, Ph.D.  
  1515 Holcombe Boulevard, Unit 447  
Houston, TX 77230  
  Telephone: (713) 794 -4158  
  Fax: (713) 563 -4242  
              jjlee@mdanderson.org  
 
Organization:   University of Texas MD Anderson Cancer Center  
Protocol  Statistician:   Diane Liu  
  1515 Holcombe Boulevard, Unit 447  
Houston, TX 77230  
  Telephone: (713) 794 -4175  
  Fax: (713) 563 -4242  
dianeliu@mdanderson.org  
 
Organization:   Northwestern University  
Consultant:   Seema Khan , MD  
          Department of Surgery  
      303 East Superior Street  
      Chicago, IL 60611  
      (312)503 -4236 office  
      (312)503 -2555 fax  
       s-khan2@northwestern.edu   
 
Medical Monitor   Marjorie Perloff, MD  
Chemopreventive Agent Development Research Group  
Division of Cancer Prevention  
9609 Medical, Rm 5E544  
Rockville, MD 200850  
Office Tel (240)276 -7097  
Cell (240)731 -1772  
FAX (240)276 -7847  
Email: perloffm@mail.nih.gov  
 
 
 
 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –3– 
08/31/2016    
 
Scientific Monitor:   Brandy Heckman -Stoddard, PhD, MPH  
  Breast and Gynecologic Cance r Research Group  
  Division of Cancer Prevention  
  9609 Medical Center Dr.  
  Bethesda, MD 20892 -9783  
  Phone number: (240)276 -7048  
  Fax number: (240)276 -7828  
  Email:  heckmanbm@mail.nih.gov  
 
 
IND Sponsor:   NCI DCP  
 
IND#    Exempt  
 
Agent(s)/Supplier : Targretin® (bexarotene) gel 1% / Valeant Pharmaceuticals  
 
NCI Contract #   HHSN261201200034I  
 
Protocol Version Date:   4/27/2021  
 
Protocol Revision or   
Amendment #   Version 14 
 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –4– 
08/31/2016   SCHEM A 
A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer  
 
Part 1: Dose Escalation  Group  
Screening/Baseline Clinic Visit Day -30 to 0  
Women with ADH, ALH, LCIS , Breast cancer survivors  (DCIS or invasive)  ≥ 5 years from their diagnosis , BRCA 1/2 
mutation  carriers , or elevated risk for breast cancer ≥1.7% in 5 years or lifetime risk ≥20%  
 
Intervention (N=3 0) Dose Assignment by a 3+3 dose escalation with 3 dose levels (Day 0):  
Bexarotene 1% gel 10mg/breast/every other day or  Bexarotene 1% gel 10mg/breast/daily or   
Bexarotene 1% gel 20mg/breast/daily  for treatment duration of 4 weeks  
 
Start Treatment (Day 1)  
 
Phone Call  (Day 8)   
Assess AEs and review Gel Diary 
 
Study Visits ( Day 15 and Day 28 (End of Study) ) 
Assess  for AEs & review gel diary. Labs to assess safety ( CBC, LFTs , Lipid Profile, Thyroid Function Tests, Calcium) 
on Day 15 and 28 visits. Serum bexarotene collected on Day 0 and  Day 28  visit. Optional breast biopsy at Day 28 visit.  
 
Follow Up Call ( 30 days  ± 7 days after Day 28)  
Assess for any further AE and document resolution of any acquired AE during treatment  
 
Primary Endpoint: Safety and Toxicity  
Secondary Endpoints:  Serum and Tissue Bexarotene level , calcium, lipid and thyroid function biomarkers  
 
Part 2: Dose Expansion  Group  
Screening/Baseline Clinic Visit Day -30 to 0  
Women with ADH, ALH, LCIS, Breast cancer survivors (DCIS or invasive) that are ≥ 5 years from the ir diagnosis, 
BRCA 1/2 mutation carriers, or elevated risk for breast cancer ≥1.7% in 5 years or lifetime risk ≥20%  
 
Intervention (N=1 0) (Day 0):  
Bexarotene 1% gel at maximum tolerated dose from Part A Dose Escalation Group for 4 weeks .  
 
Start Treatment (Day 1)  
Start application of bexarotene gel to one unaffected breast  
 
Phone Call (Day 8)  
Assess adverse events and review Gel Diary 
 
Study Visits (Day 15 and Day 28 (End of Study))  
Assess for AEs & review  gel diary. Labs to assess safety ( CBC, LFTs, Lipid Profile, Thyroid Function Tests, Calcium) 
on Day 15 and 28 visits. Serum bexarotene collected on Day 28 visit. Mandatory b reast biopsy at Day 28 visit.  
 
Primary Endpoint: Safety and Toxicity  
Secondary Endpoi nts: Serum and Tissue Bexarotene level, calcium, lipid and thyroid function biomarkers  
 
Follow Up Call ( 30 days  ± 7 days after Day 28)  
Assess for any further AE and document resolution of any acquired AE during treatment  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –5– 
08/31/2016   TABLE OF CONTENTS  
 
COVER PAGE  ................................ ................................ ................................ ................................ ........  1 
SCHEMA  ................................ ................................ ................................ ................................ ................  4 
1. OBJECTIVES  ................................ ................................ ................................ ................................  7 
1.1 Primary Objectives  ................................ ................................ ................................ ..................  7 
1.2 Secondary Objectives  ................................ ................................ ................................ ..............  7 
2. BACKGROUND  ................................ ................................ ................................ ...........................  7 
2.1 Breast Cancer Prevention  ................................ ................................ ................................ .........  7 
2.2 Bexarotene  ................................ ................................ ................................ ..............................  7 
2.3 Rationale  ................................ ................................ ................................ ................................ . 8 
3. SUMMARY OF STUDY PLAN  ................................ ................................ ................................ .. 10 
4. PARTICIPANT SELECTION ................................ ................................ ................................ ...... 11 
4.1 Inclusion Criteria  ................................ ................................ ................................ ...................  11 
4.2 Exclusion Criteria  ................................ ................................ ................................ ..................  12 
4.3 Inclusion of Women and Minorities  ................................ ................................ .......................  12 
4.4 Recruitment and Retention Plan  ................................ ................................ .............................  12 
5. AGENT ADMINISTRATION  ................................ ................................ ................................ ..... 13 
5.1 Dose Regimen and Dose Groups/Gel Application  ................................ ................................ .. 13 
5.2 Gel Administration /Run-in Procedures  ................................ ................................ ...................  14 
5.3 Contraindications  ................................ ................................ ................................ ...................  14 
5.4 Concomitant Medications  ................................ ................................ ................................ ...... 14 
5.5 Dose Modification  ................................ ................................ ................................ .................  15 
5.6 Adherence/Compliance  ................................ ................................ ................................ ..........  16 
6. PHARMACEUTICAL INFORMATION  ................................ ................................ .....................  16 
6.1 Bexarotene  Gel (IND #, IND Sponsor ) ................................ ................................ ...................  16 
6.2 Reported Adverse Events and Potential Risks  ................................ ................................ ........  17 
6.3  Availability  ................................ ................................ ................................ ............................  18 
6.4 Agent Distribution  ................................ ................................ ................................ .................  18 
6.5  Agent Accountability  ................................ ................................ ................................ .............  19 
6.6 Packaging and Labeling  ................................ ................................ ................................ .........  19 
6.7 Storage  ................................ ................................ ................................ ................................ .. 19 
6.8 Registration  ................................ ................................ ................................ ...........................  20 
6.9 Blinding and Unblinding Methods  ................................ ................................ .........................  20 
6.10 Agent Destruction/Disposal  ................................ ................................ ................................ ... 20 
7. CLINICAL EVALUATIONS AND PROCEDURES  ................................ ................................ ... 21 
7.1 Schedule of Events  ................................ ................................ ................................ ................  21 
7.2 Baseline Testing/Prestudy Evaluation  ................................ ................................ ....................  22 
7.3 Evaluation During Study Intervention  ................................ ................................ ....................  24 
7.4 Evaluation at Completion of Study Intervention  ................................ ................................ ..... 24 
7.5 Post-intervention Follow -up Period  ................................ ................................ ........................  25 
7.6 Methods for Clinical Procedures  ................................ ................................ ............................  25 
8.  CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION  ................................ ............  25 
8.1 Primary Endpoint  ................................ ................................ ................................ ...................  25 
8.2 Secondary Endpoints  ................................ ................................ ................................ .............  27 
8.3 Off-Agent Criteria  ................................ ................................ ................................ .................  27 
8.4 Off-Study Criteria  ................................ ................................ ................................ ..................  27 
8.5 Study Termination  ................................ ................................ ................................ .................  28 
9. CORRELATIVE/SPECIAL STUDIES  ................................ ................................ ........................  28 
9.1 Rationale for Methodology Selection  ................................ ................................ .....................  28 
9.2 Comparable Methods  ................................ ................................ ................................ .............  28 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –6– 
08/31/2016   10. SPECIMEN MANAGEMENT  ................................ ................................ ................................ ..... 28 
10.1 Laboratories ................................ ................................ ................................ ...........................  28 
10.2 Collection and Handling Procedures  ................................ ................................ ......................  28 
10.3 Shipping Instructions  ................................ ................................ ................................ .............  29 
10.4 Tissue Banking  ................................ ................................ ................................ ......................  30 
11. REPORTING ADVERSE EVENTS ................................ ................................ .............................  30 
11.1 Adverse Events  ................................ ................................ ................................ ......................  30 
11.2 Serious Adverse Events  ................................ ................................ ................................ .........  32 
12. STUDY MONITORING  ................................ ................................ ................................ ..............  33 
12.1 Data Management  ................................ ................................ ................................ ..................  33 
12.2 Case Report Forms  ................................ ................................ ................................ ................  33 
12.3 Source Documents  ................................ ................................ ................................ .................  34 
12.4 Data and Safety Monitoring Plan  ................................ ................................ ...........................  34 
12.5 Sponsor or FDA Monitoring  ................................ ................................ ................................ .. 35 
12.6 Record Retention  ................................ ................................ ................................ ...................  35 
12.7 Cooperative Research and Development Agreement (CRADA)/Clinical Trials Agreement (CTA)  35 
13. STATISTICAL CONSIDERATIONS  ................................ ................................ ..........................  36 
13.1 Study Design/Description  ................................ ................................ ................................ ...... 36 
13.2 Randomization/Stratification ................................ ................................ ................................ .. 37 
13.3 Accrual and Feasibility  ................................ ................................ ................................ ..........  37 
13.4 Primary Objective, Endpoint(s), Analysis Plan  ................................ ................................ ....... 37 
13.5 Secondary Objectives, Endpoints, Analysis Plans ................................ ................................ ... 38 
13.6 Reporting  and Exclusions  ................................ ................................ ................................ ...... 38 
13.7 Evaluation of Toxicity  ................................ ................................ ................................ ...........  39 
13.8 Evaluation of Response  ................................ ................................ ................................ ..........  39 
13.9 Interim Analysis  ................................ ................................ ................................ ....................  39 
13.10  Ancillary Studies  ................................ ................................ ................................ ...................  39 
14. ETHICAL AND REGULATORY CONSIDERATIONS  ................................ ..............................  39 
14.1 Form FDA 1572  ................................ ................................ ................................ ....................  39 
14.2 Other Required Documents  ................................ ................................ ................................ .... 39 
14.3 Institutional Review Board Approval  ................................ ................................ .....................  40 
14.4 Informed Consent  ................................ ................................ ................................ ..................  40 
14.5 Submission of Regulatory Documents  ................................ ................................ ....................  41 
14.6 Other  ................................ ................................ ................................ ................................ ..... 41 
15. FINANCING, EXPENSES, AND/OR INSURANCE  ................................ ................................ ... 41 
REFERENCES ................................ ................................ ................................ ................................ ...... 42 
APPENDIX A  ................................ ................................ ................................ ................................ ....... 43 
APPENDIX B  ................................ ................................ ................................ ................................ ....... 43 
APPENDIX C ................................ ................................ ................................ ................................ ....... 47 
APPENDIX D  ................................ ................................ ................................ ................................ ....... 60 
APPENDIX E ................................ ................................ ................................ ................................ ....... 66 
APPENDIX F................................ ................................ ................................ ................................ ........  71 
APPENDIX G ................................ ................................ ................................ ................................ ....... 74 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –7– 
08/31/2016   1. OBJECTIVES  
 
The overall objective is to evaluate the safety and toxicity of topical bexarotene 1% gel to the breast in healthy 
women  at high risk for breast can cer and bexarotene concentration in the breast tissue . 
 
 
1.1 Primary Objectives   
 
A. Dose Escalation Group  
 
We will conduct a trial to determine the recommended phase II dose of topical bexarotene 1% (w/w) gel for 
evaluation in healthy women. This will be determined by assessing the safety and toxicity of topical bexarotene 
gel application (tested at three different dose levels  by dose escalation , 10 mg (1  mL) every other day, 
10 mg (1 mL) daily, or 20  mg (2 mL) daily  to an unaffected breast of healthy wome n at high risk for breast 
cancer for a duration of 4 weeks.  
 
B. Dose Expansion Group  
 
We will conduct an intervention of topical 1% bexarotene gel to an unaffected breast of healthy women at high 
risk for breast cancer for 4 weeks at the maximum tolerated dose (MTD) as determined during the dose 
escalation group phase to assess bexarotene concentration in the breast tissue.  
 
 
1.2 Secondary Objectives   
1. To detect bexarotene concentration in the serum at baseline and at 4 weeks of treatment.  
2. To detect bexarotene concentration in the breast tissue at 4 weeks of treatment  in the dose escalation 
group . 
3. To investigate the effects of topical bexarotene on serum biomarkers we will determine the change 
from the baseline in:  
i. Lipid Biomarke rs (Total Cholesterol, triglycerides, LDL, HDL)  
ii. Thyroid Function Biomarkers (Thyroid Stimulating Hormone (TSH), T4, T3)  
iii. Calcium  
 
1.3 Exploratory Objective (Dose Expansion Group)  
 To examine changes in gene expression associated with retinoid action.  
 
2. BACKGROUND  
 
2.1 Breast Cancer Prevention  
 
Breast cancer is the most common malignancy among women in the US, and prevention of this disease is 
therefore a major public health concern. Chemoprevention with anti -estrogens, including tamoxifen, raloxifene, 
and exemestane, has been shown to reduce the  incidence of hormone receptor (HR) -positive breast cancer. 
However, agents that can reduce the incidence of hormone receptor negative breast cancer are currently lacking.  
 
2.2 Bexarotene   
 
Retinoids are vitamin A analogues that have been shown to be invo lved in cell differentiation, growth, and 
apoptosis  (1). They exert their effects by binding to two specific classes of receptors known as the retinoic acid 
receptors (RAR ) and retinoic X receptors (RXR).  Once activated, RARs and RXRs form heterodimers and 
function as transcription factors and subsequently bind to retinoic acid response elements (RARE) and regulate 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –8– 
08/31/2016   gene expression regulating cell differentiation, growth, a nd apoptosis  (2, 3) . Rexinoids are similar agents but 
only activate the RXR receptors without activating the RAR nuclear receptors. Bexarotene is a rexinoid that 
has been studied extensively and is currently an FDA approved treatment for cutaneous T cell lymphoma  
(CTCL) . 
 
Oral bexarotene was evaluated in phase 2 and 3 clinical trials for refractory or persistent early stage CTCL. 
Duvic  et al. randomized 58 patients to two doses of bexarotene at 6.5mg/m2 per day and 650mg/m2 per day 
which was later modified to 300mg/m2 per day for at least 16 weeks or until progression. Responses of greater 
than 50% improvement in skin lesions were noted  in 20% of patients at 6.5mg/m2 and 54% of patients had a 
response at  300mg/m2 and 67% of patients at doses greater than 300mg/m2. Seventy -three percent of patients 
that crossed over from 6.5mg/m2 to higher doses responded with the increased dose. H ypertri glyceridemia, 
hyperlipidemia, headache, and hypothyroidism were noted in a significant number of patients and were 
reversible with discontinuation of drug. Since increased toxicity was noted at dose level greater than 300mg/m2, 
recommended dose is 300mg/m2 in patients with refractory CTCL (4). 
 
Bexarotene has been developed as a gel and has been evaluated in clinical trials in patients with early stage 
CTCL . Based on the positive results of these studies, topical bexarotene is currently an FDA approved drug for 
the treatment of CTCL . In phase I and II trials conducted by Breneman and colleagues, topical bexarotene was 
applied to the skin lesions di rectly at different concentration levels of 0.1%, 0.5%, and 1% bexarotene gel. 
Patients started at the lowest concentration and applied the gel to affected skin lesions daily and titrated to twice 
daily dosing after 2 weeks and were tolerating the medicati on. As patients were able to tolerate gel application, 
bexarotene concentration was increased to 0.5% and then 1% and applying gel up to 4 times daily if tolerated. 
Most patients were able to tolerate 1% gel at twice daily dosing. The total dosage each pat ient received depended 
on the size and the number of lesions.  Bexarotene gel was well tolerated and the most frequent adverse events 
in 67 patients were rash (73%), prurit us (33%), and pain (24%) with most being mild to moderate in severity. 
Systemic concentrations of bexarotene were extremely low and systemic side effects noted with oral bexarotene 
such as hyperlipidemia, hypothyroidism, and hypertriglyceridemia were not detected when medication was 
applied topically (5). Bexarotene 1% gel was also evaluated in a PhaseI/II trial for alopecia areata and was 
applied to half of participants’ scalp to assess response. Out of 42 patients,  31 (73%) experienced some dermal 
irritation with only 4 patients experiencing grade 3 dermal irritation.  Most common adverse event noted was 
mild erythema in the area of treatment that resolved with discontinuation of the drug  (6). 
 
2.3 Rationale  
 
In preclinical mouse models that develop ER -negative breast cancers, bexarotene showed significant activity in 
delaying mammary tumor development. In p53 -null mice, bexarotene was given at 10mg/kg and 100mg/kg by 
gastric gavage and a 75% reduction in mammary tumor development was found in virgin mice at the higher 
dose level (7). In mouse mamm ary tumor virus (MMTV) -ErbB2 transgenic mice, focal tumors develop at eight 
months. Similar to humans, (MMTV) -ErbB2 mice undergo a multistage process of mammary tumorigenesis 
that progresses from normal mammary tissue to hyperplasia, mammary intraepithelia l neoplasia (MIN) and 
finally invasive cancer. Li and colleagues gave bexarotene at 100mg/kg by oral gavage for 2 to 4 months in 
MMTV -erbB2 transgenic mice starting at three months of age. They found that bexarotene prevented the 
development of premalignan t mammary lesions such as hyperplasia and MIN that is similar to human ductal 
carcinoma in situ (8). 
 
Based on these preclinical findings, oral bexarotene  at 200mg/m2 has been evaluated in women at high risk for 
breast cancer based on their genetic risk. Bexarotene was found to reduce cyclin D1 RNA expression in breast 
cells from postmenopausal women  (9). A nonsignificant reduction in Ki -67 expression was also seen  in these 
post-menopausal women. Significant systemic side effects such as hypertriglyceridemia, hypercholesterolemia, 
and hypothyroidism were also found and were reversible after discontinuation of the drug (9). These results 
demonstrated that bexarote ne has a biological effect on breast cells in women at high risk of breast cancer.  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –9– 
08/31/2016    
In addition to repressing cyclin D1 in breast cancer cells, bexarotene has shown effects on cyclin D1 in lung 
cancer cell lines. Dragnev et al. showed that the combination  of bexarotene  1-4µmol/L  plus erlotinib 1-4µmol/L  
significantly decreased cyclin D1 expression in cyclin -E- and KRAS/p53 -driven transgenic lung cancer cell 
lines. The combination of bexarotene 400mg/m2 per day plus erlotinib 150mg daily was evaluated in early stage 
non-small cell lung cancer patients in a window of opportunity trial and significant decreases in cyclin D1 were 
noted as well as an induction of necrosis and inflammatory responses (10).  
 
Topical Therapies in Chemoprevention  
Uptake has been low in chemoprevention  medications such as tamoxifen and raloxifene due to its systemic side 
effects of menopausal symptoms and blood clots. Topical creams applied directly to the breast could affect the 
breast tissue without leading to systemic side effects. Mauvais -Jarvis and colleagues evaluated trans -4-
hydroxytamoxifen (4 -OHT), a n active metabolite of tamoxifen, by topical administra tion to the breast. They 
evaluated 4 -OHT absorption through the skin and its metabolism. Topical 4 -OHT was applied directly over the 
breast in patients with invasive breast cancer and subsequently underwent mastectomy for their tumor. 
Concentration of 4 -OHT was evaluated in breast tissue cytosol as well as nuclear extract and plasma samples 
taken at the time of surgery. 4 -OHT was detected in the cytosol as well as in the nuclear extract as early as 24 
hours of application and decreased in concentration over  time at 7 days after application. Plasma concentrations 
of 4-OHT was low but 4 -OHT metabolites were present in the plasma but not detected in the breast tissue. This 
showed that topical application bypassed the first pass hepatic metabolism of the drug. M auvais - Jarvis et al.  
also evaluated the topical application of 4 -OHT on the breast versus the abdomen and found retention of the 
drug in the breast and delayed plasma concentrations of 4 -OHT when compared to application on the abdomen  
(11). 
 
Rouanet et al.  evaluated 4 -OHT in a pre -surgical trial of 55 postmenopausal women with invasive ER positive 
breast cancer. Patients applied 4 -OHT for 2 to 3 weeks at various dose levels compared to another group 
receiving oral tamoxifen at 20mg/day. They found that tissue proliferation decreased as measured by Ki -67 
levels between baseline and after treatment. There was a significant decrease in proliferation in the topical 
treatment arms with lower plasma concentrations of tamox ifen compared to oral treatment (12). Lee and 
colleagues evaluated 4 -OHT in women with DCIS for 6 to 10 weeks prior to surgery. Women were randomized 
to either 4 -OHT (4mg/day) or oral tamoxifen (20mg/day) and assessed change in Ki -67 in their DCIS lesions. 
Tissue concentration of drug was similar betw een 4 -OHT and oral tamoxifen whereas systemic concentrations 
of 4-OHT were lower than oral tamoxifen. Changes in proliferation were also similar across both arms. No 
serious adverse events were noted with 4 -OHT in this study. Bexarotene is similar to retin oids and thus more 
likely to have skin reactions than 4 -OHT (13). 
 
We hypothesize that topical bexarotene can be applied to the breasts as a chemoprevention agent with 
penetration to the breast tissue and without havin g high systemic levels of drug and subsequent side effects and 
toxicity as seen with oral bexarotene. Data from chemoprevention studies with topical tamoxifen support the 
concept of topical agents penetrating into the breast tissue and exhibiting biologica l activity in the tissue. 
Preclinical models have clearly shown the effect of bexarotene in reducing the incidence of estrogen receptor 
negative breast cancer. Based on this data, we propose a phase I study to evaluate topical bexarotene in women 
at elevat ed risk for developing breast cancer.  
 
Rationale for including Alcohol and Tobacco Assessment Questionnaires  
Increasing evidence suggests that tobacco and alcohol use are risk factors in the development of intraepithelial 
neoplasia and cancer. In addition, tobacco and alcohol use may adversely affect agent intervention, for example 
by altering the safety profile or metabolism of a drug. Standardized assessments of tobacco and alcohol use 
during clinical trials will aid in understanding the potential relationship between the use of these products and 
clinical endpoints or cancer prevention biomarkers. Therefore, NC I, DCP is including assessment of tobacco 
and alcohol use at baseline and (include follow -up timepoint), to determine the potential impact of tobacco and 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –10– 
08/31/2016   alcohol use on 1) treatment toxicity and symptom burden, and 2) the efficacy of treatment intervention . 
 
 
3. SUMMARY OF STUDY PLAN  
 
A. Dose Escalation Group  
We will recruit women at high risk for breast cancer to this phase I study. We will use topical bexarotene 1% 
gel and this will be applied to one unaffected breast for 4 weeks. Participants will be ass igned to one of three 
different dose levels . Bexarotene gel volume  is estimated to be 1ml for 1g of gel which contains 10mg of 
bexarotene. Therefore, the three dose cohorts will be 10mg (1ml)  every other day, 1 0mg (1ml) daily, 2 0mg 
(2ml) daily. Dose Limiti ng Toxicity (DLT) is defined as a grade 2 skin adverse event that persists for at least 6 
days or any grade 3 or greater adverse event possibly, probably, or definitely related to the study drug.   In 
addition , a DLT will be a grade 2 skin adverse event that recurs and persists for at least 3 days.   A conservative 
modification of the standard “3+3” design will be applied. The first three participants will be  assigned to the 
lowest dose level. New cohorts of 3 -4 participants  will not be treated until toxicity has been evaluated for all 
current participants  for 4 weeks.  Group assignment algorithm is explained in Section 13.4  and dose escalation 
is illustrated in Figure 1 .  The Maximum Tolerated Dose  (MTD)  will be defined as the highest dose level with  
at most 2 participants  with DLT in 10  participants  treated.   
 
Figure 1: Dose Escalation Schema for Bexarotene 1% gel  
 
 
 
 
Bexarotene gel will be provided by Valeant pharmaceuticals and repackaged by DCP pharmacy in dose metered 
pumps for dispensing the correct dose for application. Participants will begin application of the gel to the upper 
outer and upper inner quadrants of one breast every other day for one week and then increase to daily for 3 
weeks if  they are assigned to daily dosing arm. If participants are assigned to every other day dosing, they will 
continue in this manner for the entire 4 weeks. Participants that are assigned to 20 mg  (2ml)  daily will first start 
with application of 10mg  (1ml)  to the breast every other day for 1 week, then increase to 10mg (1ml) daily for 
1 week, and then increase to 20mg (2ml) daily for the remaining 2 weeks as long as it is tolerated. Participants 
can also participate in an optional core breast biopsy of the upp er outer or inner quadrant at the end of study 
treatment and receive compensation for additional expenses associated with the biopsy, such as additional travel 
expenses, time missed from work or other expenses associated with the biopsy visit . All particip ants will need 

DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –11– 
08/31/2016   to come in for clinic visits for toxicity assessment and blood collection.  All participants will receive a follow -
up phone call from the site investigator or designee 30 days ± 7 days  after completion of study drug to assess 
for any further AE and document resolution of any acquired AE during treatment.  
 
As of Oct 2019, enrollment was completed to the first dose cohort and the second dose cohort was stopped early 
due to DLTs. No DLTs were experienced in the first dose cohort of 10 patients th at applied 10mg of bexarotene 
to the breast every other day. In the second dose cohort, participants applied 10mg daily after tolerating 
application of every other day for one week. Four participants were enrolled in this cohort and 1 participant 
withdrew early due to adverse events unrelated to study drug. Two DLTs were noted  in the remaining patients 
and thus enrollment was stopped at the second dose level. Therefore, no patients will be enrolled to the third 
dose level due to concerns for toxicity. MTD i s 10mg/breast/every other day.  
 
B. Dose Expansion Group  
A dose expansion group of additional 10 participants  will be enrolled and treated at the MTD to further evaluate 
safety and drug penetration into the breast tissue. There will be a ramp up to the desired dose similar to the 
ramp up schedule in the dose escalation group. At any time in the dose expansion cohort, if there are ≥30% 
DLT among participants, the trial will be terminated.  Assessment for dose limiting toxicities will occur 
continuously as participants  are enrolled into the dose expansion group . This will be determined after the third 
and each successive participant until  10 participants are in the group. Participants in this group will receive 
treatment for 4 weeks and undergo the same schedule of events as the dose escalation group. All participants in 
the dose expansion cohort will have a core breast biopsy at end of tr eatment  and receive compensation for 
additional expenses associated with the biopsy, such as additional travel expenses, time missed from work or 
other expenses associated with the biopsy visit . All participants will receive a follow -up phone call from the  
site investigator or designee 30 days ± 7 days  after completion of study drug to  assess for any further AE and 
document resolution of any acquired AE during treatment.  
 
 
4. PARTICIPANT SELECTION  
 
4.1 Inclusion Criteria  
4.1.1 Participants must  be at high risk as defined by a  history  of breast cancer (invasive or DCIS) and be at 
least 5 years out from diagnosis , or lobular carcinoma in situ (LCIS), or proliferative benign breast 
disease such atypical ductal hyperplasia (ADH), atypical lobular hy perplasia(ALH) or genetic test 
confirmation of BRCA 1/2 mutation carrier  or have a breast cancer risk assessment >1.7% in 5 years 
or a lifetime risk >20%.  
 
4.1.2 No evidence of disease (in situ or invasive cancer that would normally be treated by resection) at trial 
entry as determined by the investigator. Diagnosis of invasive cancer must be at least 5 years prior to 
initiation on trial.  
 
4.1.3 Female  ≥18 years  as breast cancer is extremely rare in women less than 18 years.  
 
4.1.4 ECOG performance status ≤1 (Karnofsky ≥70% ; see Appendix A)  
 
4.1.5 Participants must have normal organ and marrow function as defined below:  
  Leukocytes  ≥3,000/microliter  
  Absolute neutrophil count ≥1,500/microliter  
  Platelets  ≥100,000/microliter  
  Total bilirubin  within normal institutional limits  
  AST (SGOT)/ALT (SGPT) ≤1.5 × institutional upper limit of normal (ULN)  
  Creatinine  ≤ 1.5x institutional ULN  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –12– 
08/31/2016     Hemoglobin   ≥10 g/dL  
  TSH    within normal institutional limits  
  Triglycerides   ≤300 mg/dl  
  Total Cholesterol  ≤300 mg/dl  
 
4.1.6 ≥ 6 months from all previous breast cancer treatment (including endocrine therapy).  
 
4.1.7 Participants must have adequate accessible breast tissue as determined by the treating physician, 
consisting of one breast unaffected by invasive c ancer, which has not been radiated. A history of benign 
core biopsy of this breast will be permitted.  
 
4.1.8 Participants need to have had any breast imaging with a normal/benign (bi -rads 1 or 2) result within 
180 days of Day 0 and no further routine breast imag ing planned during the course of the study (4 
weeks). Exception: if the mammogram result was a bi -rads 0 and the imaging work -up (ultrasound 
and/or MRI) result comes back normal/benign (bi -rads 1 or 2) before treatment initiation , then 
participant is eligible.  
 
4.1.9 For women of childbearing potential; negative pregnancy testing within 72 hours prior to or on study 
visit #1 (Day 0) and willingness to use adequate contraception during the study intervention. OR Post -
menopausal defined as  any one of the following 1) prior hysterectomy, 2) absence of menstrual period 
for 1 year in the absence of prior chemotherapy or 3) absence of menstrual period for 2 years in women 
with a prior history of chemotherapy exposure who were pre -menopausal pri or to chemotherapy.  In 
women of childbearing potential, effective contraception must be used for one month prior to the 
initiation of therapy, during therapy, and for at least one month following discontinuation of therapy. 
It is recommended that two relia ble forms of contraception be used simultaneously.  If participants are 
interested in enrolling and have not met the requirement for contraception, they will be seen in  the clinic 
in 1 month for re -evaluation once they have met this requirement and ensure a ll other eligibility criteria 
is met prior to dose assignment.  
 
4.1.10  Willingness to comply with all study interventions and follow -up procedures including the ability to 
apply the study drug to the breast.  
 
4.1.11  Ability to understand and the willingness to sign a written informed consent document.  
  
4.1.12  Ability to avoid exposure  of the treated breast area  to sunlight and artificial ultraviolet light during the 
use of bexarotene gel.  
 
 
4.2 Exclusion Criteria  
 
4.2.1  History of allergic reactions attributed to compounds of similar chemical or biologic composition to 
bexarotene gel , oral or topical retinoids . 
 
4.2.2  Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection,  symptomatic 
congestive heart failure, uns table angina pectoris, cardiac arrhythmia, thromboembolic  disease, or 
psychiatric illness/social situations that would limit compliance with study requirements.  
  
4.2.3  Pregnant, or had given birth, or nursed at any time during the last 12 months.  
 
4.2.4  Women with a history of any cancer within the last 3 years, except for non -melanoma skin cancer.  See 
4.1.1 as history of breast cancer must be at least >5 years from diagnosis.  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –13– 
08/31/2016    
4.2.5  Prior bilateral breast surgery (mastectomy, segmental mastectomy, or breast augmentation surgery 
including breast implants or breast reductions)  or combination of breast radiation and surgery involving 
both breasts . 
 
4.2.6  Prior history or evidence of metastatic breast cancer  
 
4.2.7  Prior history of histologically confir med bilateral invasive breast cancer.  
 
4.2.8  Current use or <6 months since use of SERMS or Aromatase inhibitors or any other investigational 
treatment for  breast cancer  prevention or therapy.  
 
4.2.9  Skin lesions that disrupt the stratum corneum (eg . eczema, ulceration)  or any breakdown of the skin.  
 
4.2.10  Current use of a retinol containing agent or any retinoid analogue drug within the last 30 days.  
 
4.2.11  Dietary Vitamin A intake ≥5,000 IU/day  (as determined by dietary supplementation)  
 
4.2.1 2 Treatm ent with any investigational drug or investigational biologic within 30 days of initiating study 
treatment or during the study.  
 
4.2.13  History of HIV or active hepatitis C.  
 
 
4.3 Inclusion of Women and Minorities  
 
Women of all  races and ethnic groups are eligible for this trial.   
 
 
4.4 Recruitment and Retention Plan  
 
Participants will be recruited for enrollment on this trial from the cancer pr evention center , with particular 
attention to enhancing racial, ethnic and socioecon omic diversity. Prior to enrollment, the study will be 
discussed in detail with the participant, and possible toxicities will be presented. The informed consent 
document will be reviewed with the participant by the study physician or other medical staff au thorized by the 
participating institution to obtain Informed Consent. Please r efer to the study -specific Recruitment and 
Retention Plan for more details.  
 
 
5. AGENT ADMINISTRATION  
 
Intervention will be administered on an  outpatient basis. Reported AEs and potential risks are described in 
Section 6.2.  
 
 
5.1 Dose Regimen and Dose Groups /Gel Application  
 
Participants will self -administer the bexarotene gel.  Gel will be applied to one unaffected  breast after freshly 
washed, either by washcloth, shower, or bath, preferably in the morning, (in order to minimize potential transfer 
to the partner at night). If  morning shower is not possible, the subject will wash the  one unaffected  breast  with 
a washcloth before gel application, to remove the prior day’s dose. If a morning swim is planned, application 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –14– 
08/31/2016   should be after the swim. No washing or immersion in water s hould occur for at least 4 hours following gel 
application. The gel should not be used near fire, flame or while smoking since it is flammable due to alcohol. 
Once dry, the gel is no longer flammable. Detailed instructions regarding application are in Appe ndix B and a 
demonstration of gel application will occur during the Baseline/Dose Assignment  visit. The t reated breast  
should be covered at all times to avoid transfer to other people and protect from natural or artificial sunlight; 
contact is permitted af ter the treated area has been washed with soap and water and washing is allowable after 
a minimum of 4 hours post -application.  
 
Each bexarotene  gel canister will contain 33 mL gel product and will be metered to dispense 10 mg of 1% 
bexarotene gel  per pump.  Cohorts 1 and 2 will receive 1 bexarotene gel canister  contain ing 30  reliable doses . 
Cohort 3 will receive 2 bexarotene gel canister s contain ing 30  reliable doses each for a total of 60 reliable doses. 
The expansion cohort will receive either 1  or 2 bexarotene gel canister s depending on the maximum tolerated 
dose (MTD) as determined during the dose escalation group phase to assess bexarotene concentration in the 
breast tissue.  
 
 
5.2 Gel Administration/ Run-in Procedures   
 
Each Bexarotene gel cani ster will contain 30 reliable doses of product metered to dispense 1mL per actuation, 
1g of bexarotene gel per actuation. One gram of bexarotene gel contains 10mg of active bexarotene.  
 
Participants in all dose levels will be instructed to apply the gel at 10mg  (1 mL)  every other day to one 
unaffected breast for the first 7 days of treatment. After the Day 8 phone call  and confirmation that toxicity is 
at an acceptable range, participants assigned to 1 0mg/breast/daily will increase applications to daily. 
Participants assigned to 1 0mg/breast/eve ry other day will continue to apply gel every other day.  Participants 
assigned to 20mg/breast/daily will increase from  10mg (1mL)  every other day to daily application for another 
7 days. After the Day 15 visit and confirmation of acceptable toxicity, parti cipants will increase to 20mg (2 
mL) to the one unaffected breast daily for the remaining 2 weeks.  All participants will continue to apply the 
gel to one unaffected breast as directed for a duration of 4 weeks.  Participants in the dose expansion group wil l 
apply the gel with the same ramp up schedule as those in the dose escalation group for that dose level.  
 
Participants will also receive moisturizing lotion [CeraVe] that can be applied to the breast to reduce and prevent 
redness that can be related from the study drug. CeraVe will be provided to all participants  and they will be 
instructed to apply to the treated breast in the evening or at least 4 hours after application of study drug so it 
will not interfere with the absorption of study drug.  
 
 
5.3 Contraindications  
 
Participants are to avoid exposure of the treated breast skin to natural or artificial sunlight. This includes 
sunbathing or the use of tanning beds with the breasts exposed. Also, women who have dermatologic conditions 
causing the breakdown of skin should  not use bexarotene  gel.  
 
 
5.4 Concomitant Medications  
 
Women who are receiving endocrine therapy for breast cancer treatment or chemoprevention including 
tamoxifen, letrozole, anastrozole, fulvestrant, or exemestane at the time of screening will not be e ligible. 
Participants may not have a history of allergic reactions attributed to compounds of similar chemical or biologic 
composition to bexarotene or retinoids . Participants must limit vitamin A intake to <5,000 IU/day. Participants 
should not concurrent ly use products that contain DEET (N,N -diethyl -m-toluamide), a common component of 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –15– 
08/31/2016   insect repellant products. Otherwise, there are no restrictions on other medications, herbs, and vitamin and 
mineral supplements (other than study agents) while participatin g in the study.  
 
All medications (prescription and over -the-counter), vitamin and mineral supplements, and/or herbs taken by 
the participant will be documented on the concomitant medication CRF and will include: 1) start and stop date, 
dose and route of a dministration, and indication. Medications taken for a procedure ( e.g., biopsy) should also 
be included.  
 
 
5.5 Dose Modification  
 
For any grade 1 adverse events or grade 2  adverse events  that are not hypertriglyceridemia or skin related , no 
dose modific ations will be made. For any grade 2 skin  toxicity possibly, probably, or definitely related to study 
drug that persists for 3 days, drug will be held  for 3 days. Participants at the lowest dose level will restart gel 
application at every 3 days dosing for 3 days  (1 dose)  and then increase back to every other day dosing. I f grade 
2 skin toxicity recurs and persists for 3 days, drug application will be discontinued  and will be classified as a 
DLT . Participants in the second dose level (1 0mg daily) wil l hold for 3 days if toxicity is noted and resume at 
10mg every other day  for 4 days  (2 doses)  and then increase back to daily dosing . Participants at the highest 
dose level (2 0mg daily) will hold for 3 days and resume at 1 0mg daily  for 3 days  (3 doses)  and then increase 
back to 20mg daily . Participants  experiencing Grade 3 or Grade 4 toxicities of any attribution will be taken off 
study drug.  Please see Table 1  for dose modification algorithm.  
 
Table 1 : Dose Modification Algorithm for Grade 2 Skin Adverse Events related to Bexarotene Gel  
 
Dose Level  If Grade 2 Skin AE 
Persists for 3 Days Dose Modification  
(If Skin AE resolves to 
≤ Grade 1)  If Grade 2 Skin  AE  
Recurs and Persists for 
3 Days 
10mg/breast/every 
other day  Hold Study Drug  
for 3 days  Restart drug application 
at 10mg/breast/every 
three days  for 3 days (1 
dose) and then increase 
to original dose  Stop Drug  
10mg/breast/daily  Hold Study Drug  
for 3 days  Restart drug application 
at 1 0mg/breast/every 
other day  for 4 days  ( 2 
doses)  and then increase 
to original dose  Stop Drug  
20mg/breast/daily  Hold Study Drug  
for 3 days  Restart drug at 
10mg/breast/ daily  for 3 
days (3 doses)  and then 
increase to original dose  Stop Drug  
 
Hypertriglyceridemia is a known systemic side effect with oral bexarotene formulation and will be monitored 
throughout the study. If grade 1 hypertriglyceridemia is noted, lipid profile will be continued to monitor weekly 
and a t Day 22 blood specimen will be added for monitoring.  If grade 2 hypertriglyceridemia is noted, drug will 
be held for 1 week and triglycerides will be rechecked. If normal, drug application will be resumed at the 1 dose 
level below. If triglycerides continue to be elevated or increase again, drug will be discontinued. If grade 3 
hypertrigly ceridemia is noted, drug will be discontinued and participant will be initiated on a statin.  
Triglycerides will be checked weekly until resolution and if elevation persists after 30 days, participant will be 
referred to their primary care physician  for further management.  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –16– 
08/31/2016    
 
5.6 Adherence/Compliance  
 
5.6.1  Participants will be considered compliant if they took 75% of their bexarotene gel dose.  
 
5.6.2  The following method s will be used to monitor each participant’s agent compliance:  
1) Participants will be given a Gel Diary  and instructed to initial it each time a dose is taken.  
2) Canisters will be weighed when released and also upon return.  
 
 
6. PHARMACEUTICAL INFORMATION  
 
6.1 Bexarotene  (IND #, NCI, Division of Cancer Prevention )   
 
Targretin® (bexarotene) 1% gel contains bexarotene and is inten ded for topical application . Bexarotene is a 
member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors 
have biologic activity distinct from that of retinoic acid receptors (RARs). The chemical name is 4 -[1-(5,6,7,8 -
tetrahydro -3,5,5,8,8 -pentamethyl -2-naphthalenyl)ethenyl] benzoic acid, and the structural formula is as 
follows:  
 
Bexarotene is an off -white to white powder with a molecular weight of 348.48 and a molecular formula of 
C24H28O2. It is insoluble in water and slightly soluble in vegetable oils and ethanol, USP. Bexarotene gel is a 
clear gelled solution containing 1.0% (w/w) bexarotene in a base of dehydrated alcohol, USP, polyethylene 
glycol 400, NF, hydroxypropyl cellulose, NF, and butylated hydroxytoluene, NF.  
 
Plasma concentrations of bexarotene were determined during clinical studies in pati ents with CTCL or 
following repeated single or multiple -daily dose applications of bexarotene gel 1% for up to 132 weeks. Plasma 
bexarotene concentrations were generally less than 5 ng/mL and did not exceed 55 ng/mL. However, only two 
patients with very in tense dosing regimens (> 40% BSA lesions and QID dosing) were sampled. Plasma 
bexarotene concentrations and the frequency of detecting quantifiable plasma bexarotene concentrations 
increased with increasing percent body surface area treated and i ncreasing quantity of bexarotene  gel applied. 
The sporadically -observed and generally low plasma bexarotene concentrations indicated that, in patients 
receiving doses of low to moderate intensity, there is a low potential for significant plasma concentrations 
follow ing repeated application of bexarotene gel.  Bexarotene is highly bound (>99%) to plasma proteins.  The 
plasma proteins to which bexarotene binds have not been elucidated, and the ability of bexarotene to displace 
drugs bound to plasma proteins and the abi lity of drugs to displace bexarotene binding have not been studied.  
The uptake of bexarotene by organs or tissues has not been evaluated.  
 
 
Four bexarotene metabolites have been identified in plasma following oral administration of bexarotene: 6 - and 
7-hydroxy -bexarotene and 6 - and 7 -oxo-bexarotene.  In vitro studies suggest that cytochrome P450 3A4 is the 
major cytochrome P450 responsible for formation of the oxidative metabolites and that the oxidative 
metabolites may be glucuronidated.  The oxidative me tabolites are active in in vitro assays of retinoid receptor 

DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –17– 
08/31/2016   activation, but the relative contribution of the parent and any metabolites to the efficacy and safety of bexarotene 
gel is unknown.  
 
The renal elimination of bexarotene and its metabolites was e xamined in patients with Type 2 diabetes mellitus 
following oral administration of bexarotene.  Neither bexarotene nor its metabolites were excreted in urine in 
appreciable amounts.  
 
 
6.2 Reported Adverse Events and Potential Risks  
 
The safety of bexaroten e gel has been assessed in clinical studies of 117 patients with CTCL w ho received 
bexarotene  gel for up to 172 weeks.  In the multicenter open label study, 50 patients with CTCL received 
bexarotene  gel for up to 98 weeks.  Patients in the CTCL trials were  instructed to apply a generous layer of the 
gel to the CTCL lesion starting at every other day dosing and and gradually applied more frequently up to two 
or four times a day.  This area was variable by patient but resulted in a larger volume compared to t his phase I 
trial in which is the application is limited to 1ml of bexarotene gel to only one breast which is approximately 
1% of the body surface area. The mean duration of therapy for these 50 patients was 199 days.  The most 
common adverse events report ed with an incidence at the application site of at least 10% in patients with CTCL 
were rash, pruritus, skin disorder, and pain. Adverse events leading to dose reduction or study drug 
discontinuation in at least two patients were rash, contact dermatitis, and pruritus.  
Of the 49 patients (98%) who experienced any adverse event, most experienced events categorized as mild (9 
patients, 18%) or moderate (27 patients, 54%).  There were 12 patients (24%) who experienced at least one 
moderately severe adverse eve nt.  The most common moderately severe events were rash (7 patients, 14%) and 
pruritus (3 patients, 6%).  Only one patient (2%) experienced a severe adverse event (rash). In the patients with 
CTCL receiving bexarotene  gel, adverse events reported regardles s of relationship to study drug at an incidence  
of ≥5% are presented in Table 2 (5). 
 
 
Table 2 . Incidence of All Adverse Events* and Application Site Adverse Events with Incidence ≥5% for 
All Application Frequencies of Bexarotene Gel in the Multicenter CTCL Study  
 
Body System/Preferred Term  All Adverse Events  Application Site Adverse  Events  
 N = 50  
n (%)  N = 50  
n (%)  
Skin and Appendages  
          Contact Dermatitis1 7 (14)  4 (8)  
          Exfoliative Dermatitis  3 (6)  0 
          Pruritus2 18 (36)  9 (18)  
          Rash3 36 (72)  28 (56)  
          Maculopapular Rash  3 (6)  0 
          Skin Disorder (NOS)4  13 (26)  9 (18)  
          Sweating  3 (6)  0 
Body as a Whole  
          Asthenia  3 (6)  0 
          Headache  7 (14)  0 
          Infection  9 (18)  0 
          Pain 15 (30)  9 (18)  
Cardiovascular  
          Edema  5 (10)  0 
          Peripheral Edema  3 (6)  0 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –18– 
08/31/2016   Hemic and Lymphatic  
          Leukopenia  3 (6)  0 
          Lymphadenopathy  3 (6)  0 
          WBC Abnormal  3 (6)  0 
Metabolic and Nutritional  
          Hyperlipemia  5 (10)  0 
Nervous  
          Paresthesia  3 (6)  3 (6)  
Respiratory  
          Cough Increased  3 (6)  0 
          Pharyngitis  3 (6)  0 
 
* Regardless of association with treatment  
Includes Investigator terms such as:  
1 Contact dermatitis, irritant contact dermatitis, irritant dermatitis  
2 Pruritus, itching, itching of lesion  
3 Erythema, scaling, irritation, redness, rash, dermatitis  
4 Skin inflammation, excoriation, sticky or tacky sensation of skin; NOS = Not Otherwise Specified  
 
Bexarotene 1% gel was also evaluated i n a PhaseI/II trial for alopecia areata and was applied to half of 
participants’ scalp to assess response. Out of 42 patients, 31 (73%) experienced some dermal irritation with 
only 4 patients experiencing grade 3 dermal irritation.  Most common adverse eve nt noted was mild erythema 
in the area of treatment that resolved with discontinuation of the drug (6). 
 
 
6.3  Availability  
 
Bexarote ne 1% gel will be supplied by Valeant Pharmaceuticals and will be repackaged in metered dose pumps 
by the Division of Cancer Prevention (DCP), NCI.  
 
Each  bexarotene gel canister will contain  30 reliable doses of product metered to dispense 1mL per actuati on, 
1g of bexarotene gel per actuation. One gram of bexarotene gel contains 10mg of active bexarotene.  
 
Cohorts 1 and 2 will receive 1 bexarotene gel canister  contain ing 30  reliable doses . Cohort 3 will receive 2 
bexarotene gel canister s contain ing 30  reliable doses each for a total of 60 reliable doses.  
 
The expansion cohort will receive either 1 or 2  bexarotene gel canister s depending on the maximum tolerated 
dose (MTD) as determined during the dose escalation group phase to assess bexarotene concentration in the 
breast tissue.  
 
 
6.4 Agent Distribution  
 
Agents will only be released by NCI, DCP after documentation of IRB approval of the DCP -approved protocol 
and consent is provided to DCP and the collection of all Essential Documents is complete (see DCP website for 
description of Essential Documents).  
 
NCI, DCP -supplied agents may be requested by the Investigator (or their authorized designees) at each 
Organization. DCP guidelines require that the agent be shipped directly to the ins titution or site where the agent 
will be prepared and administered. DCP does not permit the transfer of agents between institutions (unless prior 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –19– 
08/31/2016   approval from DCP is obtained). DCP does not automatically ship agents; the site must make a request . Agents 
are requested by completing the DCP Clinical Drug Request form (NIH -986) (to include complete shipping 
contact information) and faxing or mailing the form to the DCP agent repository contractor:  
 
John Cookinham  
MRIGlobal  
DCP Repository  
1222 Ozark Street  
North Kansas City, MO 64116  
Phone:  (816) 360 -3805  
FAX:  (816) 753 -5359  
Emergency Telephone: (816) 360 -3800  
 
6.5  Agent Accountability  
 
The Investigator, or a responsible party designated by the Investigator, must maintain a careful record of the 
inventory and disposition of all agents received from DCP using the NCI Drug Accountability Record Form 
(DARF) or an institutionally -approved acc ountability system. The Investigator is required to maintain adequate 
records of receipt, dispensing and final disposition of study agent. This responsibility may be delegated to the 
site coordinator, institutional pharmacist or their designees.  Include on receipt record from whom the agent 
was received and to whom study agent was shipped, date, quantity and batch or lot number. On dispensing 
record, note quantities and dates study agent was dispensed to and returned by each participant. Dr. Thoma s or 
her representatives will be responsible for study agent accountability for participants at UT MD Anderson 
Cancer Center. DCP requirements for agent accountability and the required forms are available on the DCP 
website.  
 
6.6 Packaging and Labeling  
 
Bexarotene gel  is packaged by NCI, DCP  Repository .  
 
Bexarotene gel is packaged in a container -closure system which consists of a pouch in a canister, a 1 mL 
pump, and a protective cap that covers the pump. A single actuation delivers 1mL of gel at 1g/mL. Ea ch 
canister will have a label printed with the concentration and weight of gel, expiration date, protocol number 
and “Bexarotene 1% Gel” along with the statement “Caution: New Drug - Limited by Federal law (US) to 
investigational use”. Each canister is pack aged in a carton with the sample label. Detailed instruction for gel 
application will be provided.”  The canister will also have a bright label “DO NOT DISCARD - PLEASE 
RETURN TO CLINIC” . 
 
6.7 Storage  
 
All study drug must be stored in a secure limited -acces s area . Store at 25°C (77°F) with excursions permitted 
to 15° -30°C (59° -86°F) in accordance with labeled storage requirements. Avoidance of humidity and protecting 
from light is not necessary and packaging will provide this protection.  Investigational labe ling will include 
instructions to keep the product out of the reach of children.  
 
 
 
6.8 Registration  
 
Screening and Registration into the DMI Database :  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –20– 
08/31/2016   Once informed consent has been signed , participants  will be registered into the DMI database .  The DMI 
database will assign a  participant’s PID upon completion of the registration process.  
 
Screening/Registration into site -specific databases:  
The DMI is the database of record for the study. Registration sh ould occur per the procedures outlined above. 
If the site staff needs to enter study data into site -specific electronic databases per institutional requirements, 
they should do so in accordance with their institutional policies and procedures.  
 
Appropriate CRFs must be completed for any participant who signs an informed consent. If a consented 
participant is a screen failure and deemed ineligible, the following CRFs must be completed: 1) the Registration 
CRF; 2) the Inclusion and Exclusion CRFs s howing why the participant is ineligible, 5) the Off -Study CRF, 4) 
the Adverse Event CRF, 5) the Concomitant Medication CRF and 6) the Verification CRF. If no Adverse Event 
and/or Concomitant Medications were assessed by the time the participant is deemed ineligible, the “NONE” 
box will be checked to complete both CRFs.  All participants who sign an informed consent must formally go 
off study. All participant registration information will be entered into DMI. If a participant experiences a serious 
Adverse E vent during the screening process, a Serious Adverse Event (SAE) form must be completed.  
 
 
6.9 Blinding and Unblinding Methods  
 
This is not a blinded study. Participants and the PI’s team will not be blinded to the dose of bexarotene gel.  
 
 
6.10 Agent Destruction/Disposal  
 
At the completion of investigation, all undispensed study agent will be returned to NCI, DCP Repository 
according to the DCP “Guidelines for AGENT RETURNS” and using the DCP form “Return Drug List”.  The 
Guidelines and form are available on the DCP website. Unused drug, that has been dispensed to participants, 
but that is returned unused by the participants, will be disposed of by the site staff  following institutional 
guidelines after canisters have been weighed and the weights have been recorded.  
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –21– 
08/31/2016   7. CLINICAL EVALUATIONS AND PROCEDURES  
 
7.1 Schedule of Event s 
 
Evaluation/  
Test Baseline 
Testing/Prestudy 
Evaluation/ 
Registration ( Within 
30 days prior to or on 
Day 0)  Day 0  Day 1  Day 8 
±2 days  
 
Phone 
Call Day 15 
±2 days  Day 28 
±2 days  
 Follow 
Up Call  
 
30 days  ± 
7 days 
after Day 
28 
Informed Consent  X       
Registration  X       
Medical History  X     X  
Confirm Eligibility   X      
Dose assignment   X      
Baseline Symptom 
Assessment  X       
Concomitant Medications  X     X X 
Vitals  X    X X  
Physical Exam  X       
Breast Exam  X    X X  
Breast Cup Size  X       
Weight/ Height/ Last 
Menstrual Perioda X     X  
Routine Laboratory Testsb X    X X  
Pregnancy Testc X X    X  
Research  Blood Sampled   X    X  
Breast Imaginge X       
Dispense Study Agentf  X      
Start Study Medication    X     
Adverse Events/ Symptom 
Assessment     X X X X 
Dermatology Evaluationg     X X  
Review Gel Diary   X  X X X  
Collect Study Agent       X  
Core Biopsyh      X  
Tobacco and Alcohol Use 
Assessment  Xi     Xj  
Telephone Contact     X   X 
 
a) Do not repeat height measurement and last menstrual period data collection after Baseline Testing.  
b) Routine laboratory tests include: CBC (hemoglobin, hematocrit, RBC, WBC, platelet count) with differential 
(neutrophils, lymphocytes, monocytes, eosinophils, basophils) and CMP (Na+, K+, Cl-, CO 2 (bicarbonate), BUN, 
creatinine, glucose) , liver function tests (ALT, AST, total bilirubin, Alk Phos, Albumin), triglyerides, total 
cholesterol , high density lipoprotein (HDL), low density lipoprotein (LDL), thyroid stimulating hormone (TSH), 
free T3 and free T4, and calcium.  
c) In women of child bearing potential a pregnancy test  (urine or serum)  must be done within 30 days prior to D0. 
Within 72 hours prior to or on Day 0 the pregnancy test  (urine or serum)  will be repeated and results must be 
known before starting study drug. If a urine pregnancy test is performed, the test must be done in the c linic or in 
the lab . Repeat pregnanc y test will be done at the end of study as well.   
• If pregnancy test result is positive at Baseline (any time before Day 0 ), the participant is a Screen Failure.  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –22– 
08/31/2016   • If pregnancy test result is positive on Day 0, do not dispe nse the study agent , take participant off -study, 
complete the Off -Study Case Report Form (CRF), follow the pregnancy to term and complete the Outcome 
of Pregnancy Case Report Form (CRF).  
• If a pregnancy is discovered after Day 0, instruct the participant t o stop applying the gel , take participant off -
study, complete the Off -Study CRF, follow the pregnancy to term and complete the Outcome of Pregnancy 
CRF.  
d) Research b lood sample for serum bexarotene level.  
e) Participants need to have had any breast imaging with a normal/benign  (bi-rads 1 or 2)  result  within 180 days of 
Day 0 and no further routine breast imaging planned during the course of the study (4 weeks).  Exception: if the 
mammogram result was a bi -rads 0 and the imaging work -up (ultrasound and/or MRI) result comes back 
normal/benign (bi -rads 1 or 2) before treatment initiation , then participant is eligible . 
f) Participants must be instructed to apply the last dose of their study medication on the last day o f the study (Day 
28).   
g) Dermatology evaluation within 72 hours of study visit if participant experiences a grade 3 skin event  or continues 
to have a persistent grade 2 skin event despite dose modification .  
h) The core biopsy at Day 28  is optional  for dose es calation cohort participants . The biopsy is mandatory for 
participants in the dose expansion cohort  at Day 28 . If the participant is on aspirin, non -steroidal anti -
inflammatory drugs or Vitamin E, she will be instructed to discontinue these  7 days prior to the end of treatment 
biopsy.   
i) See Appendix D “Alcohol and Tobacco Use Assessment Questionnaires – Baseline” . 
j) See Appendix E “Alcohol and Tobacco Use Assessment Questionnaires – Follow Up ”. 
 
 
7.2 Baseline Testing/Prestudy Evaluation  
 
Days -30 to 0: Baseline Testing/Prestudy Evaluation/ Registration  
The following procedures will be conducted during  Baseline Testing  or within 30 days prior to D ay 0: 
• Informed consent must be obtained prior to starting any further study procedures.  
• Registration: Once informed consent has been signed, participants will be registered into the DMI 
database. The DMI database will assign a participant’s ID upon completion of the registration process. 
Participants will also be registered into site -specific  registry databases as applicable.  
• Medical history, to include a review of breast cancer history (if applicable) and previous medical 
history, previous surgeries, reproductive history, family history, demographic information, including 
age and race.  
• Use of concomitant medications will be reviewed.  
• Baseline symptom assessment.  
• A physical examination to include vital signs (blood pressure, heart rate, respiratory rate) and breast 
exam . Breast c up size will be documented.  
• Height, weight to calculate body ma ss index (BMI).   The day of the last menstrual period will be 
recorded.  
• Pre-study routine laboratory evaluations will include the following:  
- HEMATOLOGY: CBC (hemoglobin, hematocrit, RBC, WBC, platelet count) with 
differential (neutrophils, lymphocytes, mon ocytes, eosinophils, basophils  
- CHEMISTRY: Na+, K+, Cl -, CO2, BUN, creatinine, glucose  
- Liver Function: ALT, AST, Tbili, Alk Phos, Albumin  
- Lipid profile, thyroid function tests, and calcium  
• In women of child bearing potential, a pregnancy test  (urine or seru m) must be done within 30 days 
prior to D0. Within 72 hours prior to or on Day 0 the pregnancy test  (urine or serum)  will be repeated 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –23– 
08/31/2016   and results must be known before starting study drug. If a urine pregnancy test is performed, the test 
must be done in the  clinic  or in the lab . 
- If pregnancy test result is positive at Baseline (any time before Day 0 ), the participant is a 
Screen Failure.  
- If pregnancy test result is positive on Day 0, do not dispense drug, take participant off -
study, complete the Off -Study Ca se Report Form (CRF), follow the pregnancy to term and 
complete the Outcome of Pregnancy Case Report Form (CRF).  
- If a pregnancy is discovered after Day 0, instruct the participant to stop taking drug, take 
participant off -study, complete the Off -Study CRF,  follow the pregnancy to term and 
complete the Outcome of Pregnancy CRF.  
• Participants need to have had any breast imaging with a normal/benign  (bi-rads 1 or 2)  result  within 
180 days of Day 0 and no further routine breast imaging planned during the course of the study (4 
weeks).  Exception: if the mammogram result was a bi -rads 0 and the imaging work -up (ultrasound 
and/or MRI) result comes back normal/benign (bi -rads 1 or 2) before treatment initiation , then 
participant is eligible . 
• Tobacco and Alcoho l Use Assessment, using the Baseline questionnaires. See Appendix D “Alcohol  
and Tobacco Use Assessment Questionnaires – Baseline” . Refer to Appendix F for resources for 
alcohol and tobacco quitting. These resources can be given to individuals if there is concern about 
alcohol or tobacco dependence. It is not expected that investigators will refer individuals for assistance 
or that they will undertake the care of individuals for alcohol or tobacco dependence.  
• Confirm eligibility: At the completion of the sc reening period, eligibility must be confirmed. Only after 
eligibility is confirmed, eligible participants can be assigned to a dose level and scheduled for the on 
study  tests and procedures.  
Day 0  
The following procedures will be conducted on Day 0:  
• For wo men of childbearing potential a pregnancy test  must be completed within 72 hours prior to or on 
Day 0. Either a serum or urine pregnancy test may be performed. If a urine pregnancy test is performed, 
the test must be done in the clinic  or in the lab : 
- If pregnancy test result is positive on Day 0, do not dispense drug, take participant off -
study, complete the Off -Study Case Report Form (CRF), follow the pregnancy to term and 
complete the Outcome of Pregnancy Case Report Form (CRF).  
- If a pregnancy is discov ered after Day 0, instruct the participant to stop taking drug, take 
participant off -study, complete the Off -Study CRF, follow the pregnancy to term and 
complete the Outcome of Pregnancy CRF.  
- Study drug should be init iated on the second or third day of a n ormal menstrual period.  
• Research Blood Sample for serum bexarotene concentration .  
•  
• Depending on the dose assignment , participants will receive:  
o Bexarotene 1 %  gel 1 0mg/breast/ every other da y x 4 weeks  
o Bexarotene 1% gel  1 0mg/breast/daily x 4 weeks  
o Bexarot ene 1% gel  2 0mg/breast/daily x 4 weeks  
• Review guidelines for gel application with the participant.  
• Review Gel Diary with the participant (see Appendix C). Provide instructions on use of diary.  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –24– 
08/31/2016   All data will be captured on the appropriate eCRFs.  
 
 
7.3 Evaluation During Study Intervention  
 
Day 1  
• Participants will initiate study agent on Day 1.  
Day 8 ±2 days: Phone Call  
• Participants will receive a phone call from the PI or designee for an assessment of adverse events .  To 
assess skin toxicity please ask the participant non -leading questions such as “Have you noted any 
changes in the skin of your breast?”  If the participant reports yes, then utilize the plain language guide 
(Appendix G) to ask more probing questions as n eeded. Refer to Table 3 for modified CTCAE for 
assessing skin toxicity of bexarotene gel applied to the breast skin.  
• Gel diary will be reviewed.  
 
Day 15 ±2 days  
• Participants will return for an assessment of adverse events and breast exam.  To assess skin  toxicity 
please ask the participant non -leading questions such as “Have you noted any changes in the skin of 
your breast?”  If the participant reports yes, then utilize the plain language guide (Appendix G) to ask 
more probing questions as needed. Refer t o Table 3 for modified CTCAE for assessing skin toxicity of 
bexarotene gel applied to the breast skin. Gel diary will be reviewed. Vital signs will be measured. 
Routine blood sample will be obtained during the visit  to evaluate for systemic toxicity .  
• All skin AEs will be photographed by medical photography services.  
• If Grade 3 adverse event is noted on exam, drug will be held and participant will be evaluated by 
dermatology within 72 hours of the study visit.  
 
7.4 Evaluation at Completion of Study Intervention  
Day 28 ±2 days  
• Participants will return for an assessment of adverse events and breast exam . To assess skin toxicity 
please ask the participant non -leading questions such as “Have you noted any changes in the skin of 
your breast?”  If the participant reports yes, then utilize the plain language guide (Appendix G) to ask 
more probing questions as needed. Refer to Table 3 for modified CTCAE for assessing skin toxicity of 
bexarotene gel applied to the breast skin.    Medical history and concomitant medications will be 
reviewed. Gel diary will be reviewed and collected. Routine and r esearch blood sample s will be 
obtained during the visit. Pregnancy test will be repeated at this visit. The breast core biopsy will be 
scheduled at this visit  for those participants in the dose escalation cohort who opt for the procedure and 
for all participants in the dose expansion cohort.  Breast t issue will be evaluated  for bexarotene 
concentration. Remaining study drug will be collected at this visit.  
• Vital signs will be measured.  Weight will be recorded.  
• All skin AEs will be photographed by medical photography services.  
• If Grade 3 adverse event is noted on exam, participant will be evaluated by dermatology within 72 
hours of the study visit.  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –25– 
08/31/2016   • Tobacco and Alcohol use assessment will be performed on Day 28, using the “Alcohol and Tobacco 
Use Assessment Questionnaires – Follow Up”  questionnaires (see Ap pendix E).  
 
7.5 Post-intervention Follow -up Period  
 
All participants  will receive a follow -up phone call from the site investigator or designee 30 days  ± 7 days after 
Day 28 study visit to assess for any further AE and document resolution of any acquired AE during treatment . 
If the AE has not resolved , then the participant  will be scheduled for a follow up visit with their primary care 
provider for ongoing management of this AE.   The use of concomitant medications will b e recorded.   
 
 
7.6 Methods for Clinical Procedures  
 
Breast core biopsy (see also section 10):  
 
The breast core biopsy (image guided)  will not be performed prior to drug initiation in the dose escalation 
cohort, an d is optional  at Day 28.  The breast core  biopsy (image guided)  is required of participants in the dose 
expansion group  at Day 28 . A 14 -gauge needle will be used. Every effort will be made to collect 4 cores of 
tissue, with the minimum of 3 cores per participant . Refer to Section 10 for details of specimen management.   
 
 
 
 
8. CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION  
 
8.1 Primary Endpoint : Toxicity and Safety  
 
The primary objective of this study is to determine the safety and toxicity of topical 1% bexarotene gel 
application to the breasts of healthy women at high risk for breast cancer for duration of 4 weeks. Women with 
ADH, ALH, LCIS, breast cancer survivors (DCIS or invasive) ≥ 5 years from their diagnosis, BRCA 1/2 
mutation carriers, and women with elevated risk for breast cancer ≥1.7% in 5 years or lifetime risk ≥20% will 
be recruited. Three dose levels are considered (1 0mg every other day, 1 0mg daily, and 20mg daily). Dose 
Limiting Toxicity (DLT) is defined as a grade  2 skin adverse event that persists for at least 6 days or any grade 
3 or greater adverse event possibly, probably, or definitely related to the study drug.  In addition , a DLT will be 
a grade 2 skin adverse event that recurs and persists for at least 3 days.  A conservative  modification of the 
standard “3+3” design will be applied. The f irst cohort of 3 participants  will be treated at the first dose level 
(10mg every othe r day). New cohorts of participants  will not be treated until toxicity has been  fully evaluated 
for all current participants  for 4 weeks. We  will add another 4 participants  when only 1 or less participants  
experience DLT in 6 treated participants .  We will  only escalate dose to the next higher level when 20% or less 
of total participants  experience a DLT . At any dose level, the algorithm is as follows:  
 
(1) If 0 or 1 out of 3 participants  experience DLTs (≤1/3), an additional cohort of 3 participants  will be 
treated at the same dose level. If total number of participants  experiencing DLT at that dose level is 1 
or less out of 6 (≤ 1/6), we will enroll another 4 at the same dose level.  
(2) If at any time 2 or more  participants  experience DLTs in 3 or 6 (≥ 2/3 or ≥ 2 /6) or 3 or more  experience 
DLT in 10 participants  (≥3/10), then the dose escalation will stop, and the next lower dose will be 
considered as the maximum tolerated dose (MTD).  
(3) In 10 participants  at each dose level, if we observe 2 or less DLTs, a cohort o f 3 will be treated at the 
next higher level.   If 3 or more in 10 participants  experience DLT, we will stop accrual to that level and 
above, and claim the regimen as to be too toxic for that level or above.  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –26– 
08/31/2016    
 
MTD is defined the highest dose level with at most 2  participants  with DLTs in 10 participants  treated.  
 
Once MTD is identified, we will enroll another 10 participants into MTD and these participants will have 
mandatory biopsies before and after 4 weeks of treatment.   We will continuously monitor agg regate DLTs in 
these participants together with the 10 participants treated during the dose escalation part of the study.   If at any 
time the posterior probability of observing a DLT rate of at least 20% exceeds 70%, i.e., Pr(DLT rate >=0.20 | 
Data) >70%, given the prior of the DLT rate of beta (0.2, 0.8), we will stop the trial and claim the dose is too 
toxic.     Given the above rule, the boundaries for early stopping due to excessive DLT are Total Number of 
Participants with DLTs/Total Number of Participa nts >= 4/11~14, 5/15~19, and 6/20.   Combining with the 
boundaries during dose escalation phase, i.e., stop accrual at the dose level if Total Number of Participants  with 
DLTs/Total Number of Participants  >= 2/3, 2/6, 3/10, 4/11~14, 5/15~19, and 6/20, the early stopping 
probability for this level will be 15%, 51%, 82% if the true DLT rate is 0.10, 0.20, and 0.30, respectively.  
 
Given that there are 3 dose levels and 10 participants enrolled at each level, and 10 additional participants  at 
MTD, it is anticipated that 40 participants  will be enrolled  and treated  and up to 40 will be evalua ble at the end 
of this study.  
 
Skin Toxicity  
CTCAE criteria will be utilized to grade adverse events. Skin adverse events are expected to be the most 
common in this study. Bexarotene is similar to retinoids and retinoid dermatitis is very common and can be 
managed with temporarily withholding drug and restarting at a decreased frequency until tolerated by the 
individual. Dose modifications for each dose l evel have been defined in Section 5.5 to guide management of  
participant experiences of an adverse event   
 
CTCAE criteria for skin will be modified (Table 3) for this study  as adverse events are expected to be localized 
to the breast area. This modified criteria was also utilized by Talpur et al. when they evaluated bexarotene 1% 
gel on the scalp of participants  with alopecia areata (6). Please see Table 3 for modified CTCAE criteria.   Use 
plain language when talking to the pa rticipant  about skin AEs.   Refer to Appendix G for a plain language guide 
to support both phone and in -person assessments of skin application AEs . 
 
Participants will be shown  how much area of their breast is considered 25% of the treated area so they can 
clearly describe their symptoms and the extent of the affe cted area.  They will also be instructed to draw around 
reddened areas so they can clearly see if an area is expanding or improving and relay that information to the 
study team.  
 
Table 3: Modified CTCAE for assessing skin toxicity of bexarotene gel applied to the breast skin .  These 
assessments will be made on the breast skin (application site).  
 
 Grade 1  Grade 2  Grade 3  Grade 4  
Dry Skin  No erythema or 
prurit us With erythema or 
prurit us With erythema and 
prurit us - 
Pain of Skin  Mild pain  Moderate Pain  Severe Pain  - 
Photosensitivity  Painless  erythema  Mild to Moderate 
Pain with erythema  Erythema with 
blistering  or skin 
breakdown  Erythema with 
ulceration  
Prurit us Mild, requiring 
topical intervention  Intense, with 
changes from Intense, constant, 
limiting ADL or - 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –27– 
08/31/2016   scratching, oral 
intervention needed  sleep, oral steroids 
needed  
Rash, maculopapular  Macules or papules 
<25% of treated 
area, with or without 
symptoms ( prurit us, 
burning, tightness)  Macules or papules 
>25% of treated 
area, with or 
without symptoms  
(prurit us, burning, 
tightness) , limiting 
instrumental ADL  Macules or papules 
>25% of the treated 
area, with or 
without symptoms  
(prurit us, burning, 
tightness) , limiting 
self care ADL  - 
Urticaria  Asymptomatic or 
mild symptoms, not 
requiring therapy  Moderate, limited 
local therapy 
needed, limiting 
instrumental ADL  Urticarial lesions 
covering >30% of 
application site ; 
oral or IV 
intervention 
indicated  - 
 
 
8.2 Secondary Endpoints  
 
8.2.1  Markers of Systemic Toxicity:  Based on data from oral bexarotene in women at high risk for breast 
cancer, bexarotene alters lipid levels, thyroid function, and calcium levels. Therefore, serum biomarkers to be 
tested will be  Total Cholesterol, triglycerides, LDL, HDL, TSH, free T4, free T3, and calc ium. Evaluation and 
changes in these biomarkers will be done at baseline , 15, and Day 28 visits.  
 
8.2.2  Bexarotene Concentration : Bexarotene concentration will be determined using LC -MS/MS (5500 or 
similar; AB SCIEX, Foster City, CA) according to methods d eveloped and qualified at IIT  Research Institute 
(IITRI)  for the study.   
 
 
8.2.3 Effect of Bexarotene  on Tissue Markers :  
 
i. One of the four cores collected from the core biopsies from post treatment  (all dose expansion cohort 
participants and optional for dose escalation group)  will be formalin -fixed and paraffin embedded 
(FFPE) for future histological analysis. These cores will be stored for future use.   
ii. One of the four cores collected from the cor e biopsies post treatment will be placed in RNALater  and 
utilized for future biomarker analysis such as gene expression  of RNA biomarkers.  
 
 
8.3 Off-Agent Criteria  
 
Participants may stop taking study agent for the following reasons: completed the protocol -prescribed 
intervention, AE or SAE  including a DLT , inadequate agent supply, noncompliance, concomitant medications, 
medical contraindication, or became pregnant.  Participants experiencing Grade 3 or Grade 4 toxicities of any 
attribution will be taken off study drug.  Participants will continue to be followed, if possible, for safety reasons 
and in order to collect endpoint data according to the schedule of events. Participants that receive agent but 
withdraw without initiating treatment will be replaced and will not be  followed or evaluable for DLTs . 
 
 
8.4 Off-Study Criteria  
 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –28– 
08/31/2016   Participants may go ‘off -study’ for the following reasons: the protocol intervention and any protocol -required  
follow -up period is completed,  AE/SAE,  lost to follow -up, non-compliance,  concomitant medication, medical 
contraindication, withdraw consent, death, determination of ineligibility (including screen failure), and 
pregnancy.  
 
 
8.5 Study Termination  
 
NCI, DCP as the study sponsor has the right to discontinue the study at any time.  
 
 
9. CORRELA TIVE/SPECIAL STUDIES  
 
9.1 Rationale for Methodology Selection  
 
Section 8 outlines our primary and secondary endpoint biomarkers. The primary endpoint measurement will be 
done by assessing toxicity and adverse events using  modified  CTCAE criteria and standard clinical methods. 
CTCAE criteria for skin will be modified (Table 3) for this study as adverse events are expected to be localized 
to the breast area. This modified criteria was also utilized by Talpur et al.  when they evaluate d bexarotene 1% 
gel on the scalp of patients with alopecia areata (6). For secondary endpoints, again, we choo se methods that 
have been previously published, either by our group or other investigators, that are widely available, practical, 
and financially preferable.  
 
 
9.2 Comparable Methods  
 
The methodologies described above are those previously used (see detail s above), and the resulting data will be 
able to be compared to existing data.  
 
 
10. SPECIMEN MANAGEMENT  
 
10.1 Laboratories  
 
10.1.1  Bexarotene concentration analysis in the serum and breast tissue will be performed in Dr. Miguel 
Muzzio’s laboratory  at IITRI . 
 
10.1.2  Thyroid function tests, lipid profile, calcium, and all standard labs  will be performed at UT MD 
Anderson Outpatient Laboratory  as MD Anderson is the only site participating in the study . 
 
 
 
10.2 Collection and Handling Procedures  
  
Blood collection :  
Peripheral blood will be obtained by venipuncture at baseline, Day 15, and at Day 28 visits. Blood will be 
collected for bexarotene concentration and other biomarkers mentioned in section 8.2.1 and 8.2.2. Fasting for 
the blood draws for lipid analysis is recommended but is not mandated.  
 
For the purpose of tracking samples: All cryovials will be  label ed to identify all sample vials.  Blood specimen 
for bexarotene level will be collected in 4mL Li - Heparin tubes such as BD 367884 Plasma Tu be, 60 USP Units 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –29– 
08/31/2016   of Lithium Heparin (spray -coated) or similar. Specimen will be centrifuged at 1000G for 15 min at -4degrees 
Celsius. Plasma will be separated and aliquoted to 0.5 -1.0 ml/tube in at least 2 vials. Plasma specimens will be 
stored in a secure  -80 degree  Celsius  freezer  (range  -70 °C to -80 °C) 
 
Breast Core Biopsy (see also section 7.6):  
The breast core biopsy (image guided) will not be performed prior to treatment initiation in the dose escalation 
cohort and is optional  at Day 28.  The breast core biopsy (image guided) is required of participants in the dose 
expansion group  at Day 28 . A 14 -gauge needle will be used. Every effort will be made to collect 4 cores of 
tissue, with the minimum of 3 cores per participant  at each time point.  
 
Planned usage of core biopsies is shown in Table 4.   
 
Core biopsy specimens # 1 and 2  will be fresh frozen in liquid nitrogen for bexarotene concentration using LC -
MS/MS (5500 or similar; AB SCIEX, Foster City, CA).  
 
Core biopsy specimens # 3 will be fixed in formalin and embedded in a single paraffin block.  One H&E slide 
will be prepared for adequacy an d histological assessment. Tissue will be considered adequate for research 
assays if the H&E stained slide from the block demonstrates at least one terminal duct lobular unit (TDLU) in 
the tissue core.  Usually each terminal duct lobular unit contains 200 to 2500 cells. If no terminal duct lobular 
units are seen, deeper sections from the tissue block will be obtained.    
 
Core biopsy specimens # 4 will be placed immediately into RNAlater.  Each biopsy sample will be placed  in 
(1) prefilled  cryovial and then stored  in a secure  4 degree  Celsius  refrigerator  (range  of 4-6 °C) for a 
minimum  of 24 hours  and up to 7 days. The cryovials  w i l l  t h e n  b e r e m o v e d  from  the refrigerator  and 
place d in a secure -80 degree  Celsius  freezer  (range  -70 °C to -80 °C).  Core #2 will be used for exploratory 
gene expression analysis.  
 
 
Table 4. Planned use of core tissue biopsies:  
Core  Preparation  Analyses  
1-2 Fresh frozen  Bexarotene concentration using LC -MS/MS 
(5500 or similar; AB SCIEX, Foster City, CA)  
3 Formalin fixed, paraffin -embedded  Used to make 5 slides and then used for 
histological evaluation at to rule out cancer and 
stored for future use .  
 
4 RNAlater at 4C then transferred to     
-80°C (range -70°C to -80°C) 
freezer  Exploratory gene expression  analysis  
 
 
10.3 Shipping Instructions  
 
All samples will be shipped in compliance with the International Air Transport Association (IATA) Dangerous 
Goods Regulations.  
 
At the completion of the study, all plasma specimens and tissue specimens for bexarotene concentration will be 
shipped to Miguel Muzzio at I ITRI for analysis. Samples will be sent to:  
 
Miguel Muzzio  
Analytical Chemistry  Division  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –30– 
08/31/2016   IIT Research Institute  
10 West 35th Street, 8E9 -1  
Chicago, IL 60616  
Tel: 312.567.4909  
Fax: 312.567.4466  
Email:MMuzzio@iitri.org  
 
 
10.4 Tissue Banking  
 
Biologic specimens collected during the conduct of each clinical trial that are not used during the course of the 
study will be considered deliverables under the contract and thus the property of the NCI. At s tudy completion, 
NCI reserves the option to either retain or relinquish ownership of the unused biologic specimens. If NCI retains 
ownership of specimens, the Contractor shall collect, verify and transfer the requested biologic specimens from 
the site to a  NCI-specified repository or laboratory at NCI’s expense.  
 
 
 
11. REPORTING ADVERSE EVENTS  
 
DEFINITION: AE means any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign), 
symptom, or disease temporally associated with participation in a study, whether or not related to that 
participation. This includes all deaths that occur while a participant is on a study.  
 
Please note th at all abnormal clinical laboratory values that are determined to be of clinical significance based 
on a physician’s assessment are to be reported as AEs. Those labs determined to be of no clinical significance 
or of unknown clinical significance (per the physician’s assessment) should not be reported as AEs. Any lab 
value of unknown clinical significance should continue to be investigated/followed -up further for a final 
determination, if possible.  
 
A list of AEs that have occurred or might occur  can be fo und in §6.2 Reported Adverse Events and Potential 
Risks , as well as the Investigator Brochure or package insert.  
 
 
11.1 Adverse Events  
 
11.1.1  Reportable AEs  
 
All AEs that occur after the informed consent is signed and baseline assessments are completed (including run -
in) must be recorded on the AE CR F (paper and/or electronic) whether or not related to study agent.  
 
11.1.2  AE Data Elements:  
 
The following data elements are required for AE reporting.  
• AE verbatim term  (Include at application site, if applicable)  
• NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE  v4.0) AE term  (MedDRA 
lowest level term)  
• CTCAE (MedDRA) System Organ Class (SOC)  
• Event onset date and event ended date  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –31– 
08/31/2016   • Treatment assignment code ( TAC ) at time of AE onset  
• Severity grade  
• Attribution to study agent (relatedness)  
• Whether or not the event was reported as a SAE  
• Whether or not the subject dropped due to the event  
• Outcome of the event  
 
11.1.3  Severity of AEs  
   
11.1.3.1   Identify the AE using the CTCAE version 4.0. The CTCAE provides descriptive terminology 
(MedDRA lowest level term) and a grading scale for each AE listed. A copy of the CTCAE can be found at 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
 
AEs will be assessed according to the grade associated with the CTCAE  term. AEs that do not have a 
corresponding CTCAE term will be assessed according to the general guidelines for grading used in the CTCAE 
v4.0. as stated below.  
 
 
CTCAE v4.0 general severity guidelines:  
 
Grade  Severity  Description  
1 Mild  Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated.  
2 Moderate  Moderate; minimal, local or noninvasive intervention indicated;  
limiting age -appropriate instrumental activities of daily living 
(ADL)*.  
3 Severe  Severe or medically significant but not immediately life -threatening;  
hospitalization or prolongation of hospitalization indicated; 
disabling; limiting self -care ADL**.  
4 Life-threatening  Life-threatening consequences; urgent intervention indicated.  
5 Fatal  Death related to AE.  
   
ADL  
*Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc. 
 
**Self -care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, 
and not bedridden.  
 
11.1.4  Assessment of relationship of AE to treatment  
  
The possibility that the AE is related to study agent will be classified as one of the following: not related, 
unlikely, possible, probable, definite.  
  
11.1.5  Follow -up of AEs  
 
All AEs, including lab abnormalities that in the opinion of the investigator are clinically significant, will be 
followed according to good medical practices and documented as such.   
 
 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –32– 
08/31/2016   11.2 Serious Adverse Events  
 
11.2.1  DEFINITION : Regulations at 21 CFR §312.32 (revised April 1, 2014)  defines an SAE as any  untoward 
medical occurrence that at any dose has one or more of the following outcomes : 
 
• Death 
• A life-threatening AE  
• Inpatient hospitalization or prolongation of existing  hospitalization 
• A persistent or significant incapacity or substantial disruption of the ability to perform normal life 
functions  
• A congenital anomaly or birth defect 
• Important medical events that may not be immediately life -threatening or result in death or 
hospitalization should also be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the participant  and may require intervention to  prevent one of 
the other outcomes.  
 
 
 
11.2.2  Reporting SAEs  
SAE s should be report ed to the following 3 entities: 1) NCI DCP, 2) DCP’s regulatory contractor CCSA, and 
3) MDACC, the CLO.  Detailed reporting instructions are provided below.  In addition, the site  will follow the 
IRB requirements for SAE reporting.   
 
11.2.2.1   SAEs will be reported on the DCP SAE Report Form found at 
http://prevention.cancer.gov/clinical -trials/clinical -trials -management/protocol -information -office/pio -
instructions -and-tools/2012 -consortia . 
 
11.2.2.2   Contact the DCP Medical Monitor by phone within 24 hours of knowledge of the event.  
 
Marjorie Perloff, MD  
Division of Cancer Prevention  
National Cancer Institute  
9609 Medical, Rm 5E544  
Rockville, MD 200850  
Office Tel (240)276 -7097  
Cell (240)731 -1772  
Email: perloffm@mail.nih.gov  
 
Include the following information when calling the Medical Monitor:  
• Date and time of the SAE  
• Date and time of the SAE report  
• Name of reporter  
• Call back phone number  
• Affiliation/Institution conducting the study  
• DCP protocol number  
• Title of protocol  
• Description of the SAE, including attribution to drug  
 
 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –33– 
08/31/2016   11.2.2.3   Contact the Consortium Lead Organization (CLO) PI, Dr. Powel Brown, or designee by phone, 
fax or email listed on the protocol face page within 24 hours of knowledge of the event.  The same information 
reported to the DCP Medical Monitor should be provided to the CLO PI or designee via email, phone or fax 
within 24 hours of knowledge of the event.  
 
11.2.2.4  Written SAE reports should be forwarded to DCP’s Regulatory Contractor CCS Associates, 
Inc. (CCSA; phone: 650 -691-4400) at safety@ccsainc.com within 48 hours of l earning of the event using the 
fillable PDF SAE Report Form.    
 
11.2.2.5  The CLO PI, Dr. Brown, or designee must be copied on the email sent to DCP’s Regulatory 
Contractor CCS Associates, Inc.  
 
11.2.2.6  Valeant Drug Safety ( drugsafety@valeant.com)  and Ali Hussain ( Ali.Hussain@valeant.com)  
should be copied on the email sent to DCP’s Regulatory Contractor CCS Associates, Inc.  
 
11.2.2.7   The DCP Medical Monitor and CCSA regulatory and safety staff will determine which SAEs 
require FDA submission as IND safety reports.  
 
11.2.2.8   The Site will comply with applicable regulatory requirements related to reporting SAEs to the 
IRB/IEC.  
 
11.2.3  Follow -up of SAE  
 
Site staff should send follow -up reports as requested when additional information is available. Additional 
information should be entered on the DCP SAE Report Form in the appropriate format. Follow -up information 
should be sent to DCP as soon as available. SAEs related to the study agent will be followed until resolved.  
 
12. STUDY MONITORING  
 
12.1 Data Management  
 
This study will report clinical data using the Data Management Initiative (DMI) web -based application managed 
by the Consortiu m Biostatistics and Data Management Core.  Data Management Initiative (DMI) infrastructure 
has been developed in the Division of Quantitative Sciences (DQS), MD Anderson Cancer Center.  This 
infrastructure supplies integrated database and software services  for web -based data collection, randomized 
treatment assignment, reporting, query, data download, and data quality management.  The DMI will be the 
database of record for the protocol and subject to NCI and FDA audit.  All DMI users will be trained to use the 
DMI system and will comply with the instructions in the protocol -specific “DMI User Manual” as well as 
applicable regulatory requirements such as 21 CFR; Part 11.  Data management procedures for this protocol 
will adhere to the Data Management Plan (DM P) on file at the DCP for contract HHSN261201200034I.  
 
 
12.2 Case Report Forms  
 
Participant data will be collected using protocol -specific case report forms (CRF) developed from the standard 
set of DCP Chemoprevention CRF Templates and utilizing NCI -approv ed Common Data Elements (CDEs). 
The study will utilize  electronic CRF (e -CRF) only, which will be viewed as screens in the DMI application. 
Site staff will enter data into the e -CRF in DMI. CRF amendments will be submitted to the DCP Protocol 
Information O ffice for review and approval.  Approved changes will be programmed into the DMI database by 
the Consortium Biostatistics and Data Management Core.  
 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –34– 
08/31/2016    
12.3 Source Documents  
 
Source documentation will include only those documents containing original forms of data, including clinic 
charts, shadow files, hospital charts, and physician notes.  Data recorded directly on the CRFs designated as 
source documents ( i.e., no prior written or electronic record of data) will be considered source data.  All other 
data recorded on the CRFs will not be considered source documentation.  
 
 
12.4 Data and Safety Monitoring Plan  
 
The Data and Safety Monitoring Plan for the MD Anderson Consortium is on file at the DCP.  This study will 
be monitored by the MDACC Data and Saf ety Monitoring Board (DSMB), the data and safety monitoring board 
of record for this study.   The DSMB reports to the President, or his designee, as the on -campus representative 
of The University of Texas Board of Regents. It oversees the data and patient safety issues for clinical trials 
that originate at MD Anderson; that are coordinated or analyzed by MD Anderson and are not being monitored 
by any other DSMB; or have been designated as requiring DSMB monitoring at the request of the IRB, the 
CRC, or inst itution. The primary objectives of the DSMB are to ensure that patients' rights pertaining to 
participation in a research study are protected, and that patients' interests are prioritized over the interests of the 
scientific investigation. Responsibilities  include:  
(a) Review interim analyses of outcome data (prepared by the study statistician or other responsible 
person at the time points defined in the study) approved by the IRB and additional time points as 
determined by the DSMB, and to recommend, if ne cessary, whether the study needs to be changed 
or terminated based on these analyses;  
(b) Determine whether, and to whom, outcome results should be released prior to the reporting of study 
results;  
(c) Review interim toxicity data and efficacy of treatment ; 
(d) Review major research modifications proposed by the investigator or appropriate study committee 
prior to implementation ( e.g., termination, dropping an arm based on toxicity results from the study 
or results of other studies, increasing target sample  size).  
Refer to the Data and Safety Monitoring Plan for the MD Anderson Consortium on file at the DCP for further 
details.  
 
 
12.5 Sponsor or FDA Monitoring  
 
The NCI, DCP (or their designee), pharmaceutical collaborator (or their designee), or FDA may monitor/audit 
various aspects of the study. These monitors will be given access to facilities, databases, supplies and records 
to review and verify data pertinent to the study.  
 
 
12.6 Record Retention  
 
Clinical records for all participants, including CRFs, all source documentation (containing evidence to study 
eligibility, history and physical findings, laboratory data, results of consultations, etc.), as well as IRB records 
and other regulatory document ation will be retained by the Investigator in a secure storage facility in compliance 
with Health Insurance Portability and Accountability Act (HIPAA), Office of Human Research Protections 
(OHRP), Food and Drug Administration (FDA) regulations and guidance s, and NCI/DCP requirements, unless 
the standard at the site is more stringent. The records for all studies performed under an IND will be maintained, 
at a minimum, for two years after the approval of a New Drug Application (NDA). For NCI/DCP, records will  
be retained for at least three years after the completion of the research. NCI will be notified prior to the planned 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –35– 
08/31/2016   destruction of any materials. The records should be accessible for inspection and copying by authorized persons 
of the Food and Drug Admin istration. If the study is done outside of the United States, applicable regulatory 
requirements for the specific country participating in the study also apply.  
 
 
12.7 Cooperative Research and Development Agreement (CRADA)/Clinical Trials Agreement (CTA)  
 
The agent(s) supplied by DCP, NCI, used in this protocol, is/are provided to the NCI under a Collaborative 
Agreement (CRADA, CTA) between t he Valeant Pharmac euticals North America LLC  (hereinafter referred to 
as Collaborator(s) ) and the NCI Division of Can cer Prevention. Therefore, the following obligations/guidelines, 
in addition to the provisions in the “Intellectual Property Option to Collaborator@ contained within the terms 
of award, apply to the use of Agent(s) in this study:  
 
12.7.1  Agent(s) may not b e used for any purpose outside the scope of this protocol, nor can Agent(s) be 
transferred or licensed to any party not participating in the clinical study. Collaborator(s) data for Agent(s) are 
confidential and proprietary to Collaborator(s) and shall be maintained as such by the investigators. The 
protocol documents for studies utilizing investigational agents contain confidential information and should not 
be shared or distributed without the permission of the NCI. If a n individual participating on the s tudy or 
participant’s family member requests a copy of this protocol, the individual should sign a confidentiality 
agreement. A suitable model agreement can be downloaded from the DCP website.  
 
12.7.2  For a clini cal protocol where there is an I nvestigation al Agent used in combination with (an) other 
investigational Agent(s), each the subject of different collaborative agreements, the access to and use of data 
by each Collaborator shall be as follows (data pertaining to such combination use shall hereinafter  be refe rred 
to as "Multi -party Data”).  
 
12.7.3  NCI must provide all Collaborators with prior written notice regarding the existence and nature of any 
agreements governing their collaboration with NIH, the design of the proposed combination protocol, and t he 
existence of any obligations that would tend to restrict NCI's participation in the proposed combination protocol.  
 
12.7.4  Each Collaborator shall agree to permit use of the Multi -Party Data from the clinical trial by any other 
Collaborator solely to th e extent necessary to allow said other Collaborator to develop, obtain regulatory 
approval, or commercialize its own investigational agent.  
 
12.7.5  Any Collaborator having the right to use the Multi -Party Data from these trials must agree in writing 
prior to the commencement of the trials that it will use the Multi -Party Data solely for development, regulatory 
approval, and commercialization of its own investigational agent.  
 
12.7.6  Clinical Trial Data and Results and Raw Data developed under a collab orative agreement will be made 
available exclusively to Collaborator(s), the NCI, and the FDA, as appropriate. All data made available will 
comply with HIPAA regulations.  
 
12.7.7  When a Collaborator wishes to initiate a data request, the request should fir st be sent to the NCI, who 
will then notify the appropriate investigators of Collaborator's wish to contact them.  
 
12.7.8  Any manuscripts reporting the results of this clinical trial must be provided to DCP for immediate 
delivery to Collaborator(s) for adv isory review and comment prior to submission for publication. 
Collaborator(s) will have 30 days (or as specified in the CTA) from the date of receipt for review. Collaborator 
shall have the right to request that publication be delayed for up to an addition al 30 days in order to ensure that 
Collaborator’s confidential and proprietary data, in addition to Collaborator(s)’s intellectual property rights, are 
protected. Copies of abstracts must be provided to DCP for forwarding to Collaborator(s) for courtesy re view 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –36– 
08/31/2016   as soon as possible and preferably at least three days prior to submission, but in any case, prior to presentation 
at the meeting or publication in the proceedings. Press releases and other media presentations must also be 
forwarded to DCP prior to re lease. Copies of any manuscript, abstract, and/or press release/ media presentation 
should be sent to  the Protocol Information Office at NCI_DCP_PIO@mail.nih.gov .  
    
The Protocol Information Office will forward manuscripts to the DCP Project Officer for distribution to the 
Collaborator(s). No publication, manuscript or other form of public disclosure shall contain any of 
Collaborator’s confidential/proprietary information.  
 
 
 
13. STATISTICAL CONSIDERATION S 
 
13.1 Study Design/Description  
 
This is a phase I study to evaluate the safety and toxicity of bexarotene 1% gel in healthy women  at elevated 
risk for breast cancer . A phase I dose escalation trial was designed to test the safety of three different dose levels 
and ensure the lowest dose level is safe prior to enrollment into the second dose level and so forth. Please see 
Figure 1 for the dose escalation schema.  DLT is defined as a grade 2 skin adverse event that persists for at least 
6 days or any grade 3  event or gr eater adverse event possibly, probably, or definitely related to the study drug.  
In addition , a DLT will be a grade 2 skin adverse event that recurs and persists for at least 3 days.  The MTD 
will be defined as the highest dose level with at most 2 DLTs in 10 participants  treated.  A dose expansion group 
of additional 10 patients will be accrued at the MTD for the same treatment duration of 4 weeks with required 
baseline and post treatme nt biopsies to understand safety, toxicity, and penetration of bexarotene into the breast 
tissue .  
 
 
Figure 1: Dose Escalation Schema for Bexarotene 1% gel  
 
 

DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –37– 
08/31/2016    
 
13.2 Randomization/Stratification  
 
A conservative modification of the standard “3+3” design will be applied. The first three participants will be 
assigned to the lowest dose level.  New cohorts of 3 -4 participants  will not be treated until toxicity has been 
evaluated for all current particip ants for 4 weeks.  Group assignment  algorithm  is explained in Section 13.4 . 
 
 
 
 
13.3 Accrual and Feasibility  
 
Treatment will be initiated in 10 participants per group up to 40 participants. Participants found eligible but 
who withdraw without initiating tr eatment will be replaced and will not be followed or evaluable for DLTs.  We 
plan to screen (consent) 60 participants to enroll  (initiate treatment in)  up to 40 participants.  Our estimated 
screen out rate after consent prior to study participation  is approximately 25%.  We anticipate accrual of approx. 
3 participants per month. Since accrual is done in groups of 3 -4 participants, there will be a 4 week hold in 
accrual to assess for toxicity  in the currently enrolled participants. Assumi ng that all dose levels are maximally 
accrued to, there will be 9 months of intentional hold on accrual to assess for safety and toxicity. Therefore, it 
will take approximately 21 months to complete accrual to the three dose levels and an additional 4 mont hs to 
accrue to the dose expansion cohort.  
 
 
 
13.4 Primary Objective, Endpoint(s), Analysis Plan  
 
The primary objective of this study is to determine the safety and toxicity of topical 1% bexarotene gel 
application to the breasts of healthy women at high risk for breast cancer for a duration of 4 weeks.   Women 
with ADH, ALH, LCIS, breast cancer survivors (DCIS or invasive) ≥ 5 years from their diagnosis, BRCA 1/2 
mutation carriers, and women with elevated risk for breast cancer ≥1.7% in 5 years or lif etime risk ≥20%  will 
be recruited. Three dose levels are considered (10mg every other day, 10mg daily, and 20mg daily). Dose 
Limiting Toxicity (DLT) is defined as a grade 2 skin adverse event that persists for at least 6 days or any grade 
3 or greater  adverse event possibly, probably, definitely related to the study drug. In addition, a DLT will be a 
grade 2 skin adverse event that recurs and persists for at least 3 days.  A conservative modification of the 
standard “3+3” design will be applied. The first c ohort of 3 participants  will be treated at the first dose level 
(10mg every other day). New cohort of participants  will not be treated until toxicity has been fully evaluated 
for all current participants  for 4 weeks. We  will add another 4 participants  when only 1 or less participants  
experience DLT in 6 treated participants .  We will only escalate dose to the next higher level when 20% or less 
of total participants  experience DLT. At any dose level, the algorithm is as follows:  
 
(1) If 0 or 1 out of 3 participants  experience DLTs (≤1/3), an additional cohort of 3 participants  will be 
treated at the same dose level. If total number of participants  experiencing DLT at that dose level is 1 
or less out of 6 (≤ 1/6), we will enroll another 4 participants the sam e dose level.  
(2) If at any time 2 or more participants  experiences DLTs in 3 or 6 participants  (≥ 2/3 or ≥ 2/6) or 3 or 
more participants  experience DLT in 10 participants  (≥3/10), then the dose escalation will stop, and the 
next lower dose will be considere d as the maximum tolerated dose (MTD).  
(3) In 10 participants  at each dose level, if we observe 2 or less DLTs, a cohort of 3 participants  will be 
treated at the next higher level.   If 3 or more in 10 participants  experience DLT, we will stop accrual to 
that level and above, and claim the regimen as to be too toxic for that level or above.  
 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –38– 
08/31/2016    
MTD is defined the highest dose level with at most 2 participants  with DLTs in 10 participants  treated.  
 
Once MTD is identified, we will enroll another 10 participants  into MTD and these participants  will have 
mandatory biopsies before and after 4 weeks of treatment.   We will continuously monitor aggregate DLTs in 
these participants  together with the 10 participants  treated during the dose escalation part of the study.   If at any 
time the posterior probability of observing a DLT rate of at least 20% exceeds 70%, i.e., Pr(DLT rate >=0.20 | 
Data) >70%, given the prior of the DLT rate of beta (0.2, 0.8), we will stop the trial and claim the dose is too 
toxic.     Given the abov e rule the boundaries for early stopping due to excessive DLT are Total Number of 
Participants  with DLTs/Total Number of Participants  >= 4/11~14, 5/15~19, and 6/20.   Combining with the 
boundaries during dose escalation phase, i.e., stop accrual at the dos e level if Total Number of Participants  with 
DLTs/Total Number of Participants  >= 2/3, 2/6, 3/10, 4/11~14, 5/15~19, and 6/20, the early stopping 
probability for this level will be 15%, 51%, 82% if the true DLT rate is 0.10, 0.20, and 0.30, respectively.  
 
Given that there are 3 dose levels and 10 participants  enrolled  and treated  at each level, and 10 additional 
patients at MTD, it is anticipated that 40 participants will be treated  and up to 40 will be evalua ble at the end 
of this study.  
 
 
At the end of the study, the toxicity data will be summarized for each dose level using frequency tabulation.  
The compliance of treatment application for each dose level will be presented using descriptive statistics.  
 
 
13.5  Secondary Objectives, Endpoints, Analysis Plans  
 
Secondary Objectives:  
 
1. To detect bexarotene concentration in the serum at baseline  and at 4 weeks of treatment.  
2. To detect bexarotene concentration in the breast tissue at 4 weeks of treatment  in the dose escalation 
group . 
3. To investigate th e effects of topical bexarotene on serum biomarkers  
We will determine the change from the baseline in:  
i. Lipid Biomarkers (Total Cholesterol, triglycerides, LDL, HDL)  
ii. Thyroid Function Biomarkers (Thyroid Stimulating Hormone (TSH), T4, T3)  
iii. Calcium  
 
These measurements will be summarized using mean, standard deviation and median (range) for continuous 
variables at each time point. Wilcoxon rank -sum test may be used to examine the difference of continuous 
variables between participants ’ characteristics groups. Participants ’ demographic characteristics will be 
compared between different dose levels by Wilcoxon rank -sum and Fisher’s exact test for continuous and 
categorical variables, respectively.  In order to explore the changes over time, values of bexarotene 
concentration and biomarkers in serum will be plotted as functions of time (baseline, week 1, week 2, and week 
4). Linear mixed effect model will be applied to model the biomarker change over time for all participants .  
Appropriate transformation an d regression model will be used to ensure the model fit. Estimated bexarotene 
concentration mean in the breast tissue at 4 weeks will be calculated along with a 95% confidence interval. 
Other statistical methods may be applied when appropriate.  
 
 
13.6 Reporting  and Exclusions  
 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –39– 
08/31/2016   Every reasonable attempt will be made to recover any missing data.  If any data for the primary efficacy measure 
remains missing then the change of the primary endpoint for will not be calculated and the participant  will not 
be ev aluable for the primary endpoint.  However any available data from other time points will be included in 
the repeated measure analysis.   
 
 
13.7 Evaluation of Toxicity  
 
All participants will be evaluable for toxicity from the time of their first dose of bexarotene gel .  The grade, 
attribution, onset and resolve date of all toxicities will be recorded and summarized for each dose level at the 
end of the study.  
 
 
13.8 Evaluation of Response  
 
All participants included in the study must be assessed for respons e to intervention, even if there are major 
protocol deviations or if they are ineligible.  
 
All of the participants who met the eligibility criteria (with the possible exception of those who did not   receive 
study agent) will be included in the main analy sis. All conclusions regarding secondary efficacy measures 
requiring breast biopsies will be based on eligible participants  selecting this option . 
 
Subanalyses may be performed on the subsets of participants, excluding those for whom major protocol 
deviati ons have been identified (e.g., early death due to other reasons, early discontinuation of intervention, 
major protocol violations, etc.). However, subanalyses may not serve as the basis for drawing conclusions 
concerning efficacy, and the reasons for excl uding participants from the analysis should be clearly reported. 
For all measurements of response, the 95% confidence intervals should also be provided.  
 
 
13.9 Interim Analysis  
 
There is continual  interim analysis in a modified 3+3 design for this study.  
 
 
13.10  Ancillary Studies   
 
No additional ancillary studies are planned.  
 
 
14. ETHICAL AND REGULATORY CONSIDERATIONS  
 
14.1 Form FDA 1572  
 
Prior to initiating this study, the Protocol Lead Investigator at the Lead or Participating Organization(s)  will 
provide a signed Form FDA 1572 stating that the study will be conducted in compliance with regulations for 
clinical investigations and listing the investigators, at each site that will participate in the protocol. All personnel 
directly involved in the p erformance of procedures required by the protocol and the collection of data should 
be listed on Form FDA 1572.  
 
14.2 Other Required Documents  
 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –40– 
08/31/2016   14.2.1  Current (within two years) CV or biosketch for all study personnel listed on the Form FDA 1572 and 
Delega tion of Tasks form for the Lead Organization and all Participating Organizations.  
 
14.2.2  Current medical licenses (where applicable) for all study personnel listed on Form FDA 1572 and 
Delegation of Tasks form for the Lead Organization and all Participat ing Organizations.  
 
14.2.3  Lab certification ( e.g., CLIA, CAP) and lab normal ranges for all labs listed on Form FDA 1572 for the 
Lead Organization and all Participating Organizations.  
 
14.2.4  Documentation of training in “Protection of Human Research Subjects” for all study personnel listed 
on the FDA Form 1572 and Delegation of Tasks form for the Lead Organization and all Participating 
Organizations.  
 
14.2.5  Documentation of Federalwide Assurance (FWA) number for the Lead Organization and all 
Participating Organizations.  
 
14.2.6  Signed Investigator’s Brochure/Package Insert acknowledgement form  
 
14.2.7  Delegation of Tasks form for the Lead Organization and all Participating Organizations signed by the 
Principal Investigator for each site and initialed by all study personnel listed on th e form  
 
14.2.8  Signed and dated NCI, DCP Financial Disclosure Form for all study personnel listed on Form FDA 
1572 for the Lead Organization and all Participating Organizations  
 
 
14.3 Institutional Review Board Approval  
 
Prior to initiating the study and receivin g agent, the Investigators at the Lead Organization and the Participating 
Organization(s) must obtain written approval to conduct the study from the appropriate IRB. Should changes 
to the study become necessary, protocol amendments will be submitted to the  DCP PIO according to DCP 
Amendment Guidelines. The DCP -approved amended protocol must be approved by the IRB prior to 
implementation  
 
 
14.4 Informed Consent  
 
All potential study participants will be given a copy of the IRB -approved Informed Consent to rev iew. The 
investigator will explain all aspects of the study in lay language and answer all questions regarding the study. 
If the participant decides to participate in the study, he/she will be asked to sign and date the Informed Consent 
document. The study  agent(s) will not be released to a participant who has not signed the Informed Consent 
document. Subjects who refuse to participate or who withdraw from the study will be treated without prejudice.  
 
Participants must be provided the option to allow the use of blood samples, other body fluids, and tissues 
obtained during testing, operative procedures, or other standard medical practices for further research purposes. 
If applicable, statement of this option may be included within the informed consent docum ent or may be 
provided as an addendum to the consent. A Model Consent Form for Use of Tissue for Research is available 
through a link in the DCP website.  
 
Prior to study initiation, the informed consent document must be reviewed and approved by NCI, DCP, t he 
Consortium Lead Organization, and the IRB at each Organization at which the protocol will be implemented. 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –41– 
08/31/2016   Any subsequent changes to the informed consent must be approved by NCI, DCP, the Consortium Lead 
Organization’s IRB, and then submitted to each org anization’s IRB for approval prior to initiation.  
 
 
14.5 Submission of Regulatory Documents  
 
All regulatory documents are collected by the CLO and reviewed for completeness and accuracy. Once the 
CLO has received complete and accurate documents from the Si te, the CLO will forward the regulatory 
documents to DCP’s Regulatory Contractor:  
 
 Paper Document/CD -ROM Submissions : 
 Regulatory Affairs Department  
 CCS Associates, Inc.  
 2001 Gateway Place, Suite 350 West  
 San Jose, CA 95110  
 Phone: 650 -691-4400  
 Fax: 6 50-691-4410  
 E-mail Submissions : 
 regulatory@ccsainc.com  
 
Regulatory documents that do not require an original signature may be sent electronically to the CLO for review, 
which will then be electronically forwa rded to DCP’s Regulatory Contractor.  
 
14.6 Other  
 
This trial will be conducted in compliance with the protocol, Good Clinical Practice (GCP), and the applicable 
regulatory requirements.  
 
 
15. FINANCING, EXPENSES, AND/OR INSURANCE  
 
Participants will not be responsible for non -standard of care costs of this study. Study agent will be provided at 
no cost to the participant.  Participants in the dose escalation cohort who  choose to participate in an optional 
core breast biopsy at the end of study treatment will receive compensation for additional expenses associated 
with the biopsy, such as additional travel expenses, time missed from work or other expenses associated with 
the biopsy visit. All participants in the dose expansion cohort will have a core breast biopsy at end of treatment 
and will receive compensation for additional expenses associated with the biopsy, such as additional travel 
expenses, time missed from work or other expenses associated with the biopsy visit.   If, as a result of 
participation in this study, an individual experiences injury from known or unknown risks of the research 
procedures as described in the informed consent, immediate medical care and treatment, including 
hospitalization, if necessary, will be available.  No monetary compens ation is available for the costs of medical 
treatment for an injury, thus, the participant will be responsible for the costs of such medical treatment, either 
directly or through their medical insurance and/or other forms of medical coverage.  
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –42– 
08/31/2016   REFERENCES  
 
1. Theodosiou M, Laudet V, Schubert M. From carrot to clinic: an overview of the retinoic acid 
signaling pathway. Cellular and molecular life sciences : CMLS. 2010;67(9):1423 -45. doi: 10.1007/s00018 -
010-0268 -z. PubMed PMID: 20140749.  
2. Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Advanced drug delivery reviews. 
2010;62(13):1285 -98. doi: 10.1016/j.addr.2010.07.003. PubMed PMID: 20654663; PMCID: 2991380.  
3. Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annual review of pathology. 
2011;6:345 -64. doi: 10.1146/annurev -pathol -011110 -130303. PubMed PMID: 21073338.  
4. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC, Worldwide Bexarotene 
Study G. Phase 2 and 3 clinical trial of oral bexarotene  (Targretin capsules) for the treatment of refractory or 
persistent early -stage cutaneous T -cell lymphoma. Archives of dermatology. 2001;137(5):581 -93. PubMed 
PMID: 11346336.  
5. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 tr ial of bexarotene 
gel for skin -directed treatment of patients with cutaneous T -cell lymphoma. Archives of dermatology. 
2002;138(3):325 -32. PubMed PMID: 11902983.  
6. Talpur R, Vu J, Bassett R, Stevens V, Duvic M. Phase I/II randomized bilateral half -head co mparison 
of topical bexarotene 1% gel for alopecia areata. Journal of the American Academy of Dermatology. 
2009;61(4):592 e1 -9. doi: 10.1016/j.jaad.2009.02.037. PubMed PMID: 19682769.  
7. Medina D, Kittrell F, Hill J, Zhang Y, Hilsenbeck SG, Bissonette R, B rown PH. Prevention of 
tumorigenesis in p53 -null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, 
and celecoxib. Cancer prevention research. 2009;2(2):168 -74. doi: 10.1158/1940 -6207.CAPR -08-0107. 
PubMed PMID: 19174577; PMCID:  2995265.  
8. Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, Lamph WW, Brown PH. The rexinoid, 
bexarotene, prevents the development of premalignant lesions in MMTV -erbB2 mice. British journal of 
cancer. 2008;98(8):1380 -8. doi: 10.1038/sj.bjc.6604320 . PubMed PMID: 18362934; PMCID: 2361704.  
9. Brown P, Arun, B., A. Miller, C. Isaacs, C. Gutierrez, J. Huang, S. Mohsin, I. Migliaccio, N. Sneige, 
H. Kim, K. Sexton, S. Hilsenbeck, W. Lamph, A. Negro -Vilar, K. Johnson, and R. Elledge. Phase II trial of 
bexarotene in women at high risk of breast cancer: Comparison of protein and RNA biomarkers. Cancer 
prevention research. 2008;1(7 Suppl):CN04 -. 
10. Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, 
Johnstone D, Erkmen CP , Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, Waxman S, Dmitrovsky E. 
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials 
and transgenic models. Cancer prevention research. 2011;4(6):818 -28. d oi: 10.1158/1940 -6207.CAPR -10-
0376. PubMed PMID: 21636548; PMCID: 3108499.  
11. Mauvais -Javis P, Baudot N, Castaigne D, Banzet P, Kuttenn F. trans -4-Hydroxytamoxifen 
concentration and metabolism after local percutaneous administration to human breast. Cance r research. 
1986;46(3):1521 -5. PubMed PMID: 3943109.  
12. Rouanet P, Linares -Cruz G, Dravet F, Poujol S, Gourgou S, Simony -Lafontaine J, Grenier J, Kramar 
A, Girault J, Le Nestour E, Maudelonde T. Neoadjuvant percutaneous 4 -hydroxytamoxifen decreases breast  
tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4 -
hydroxytamoxifen gel to oral tamoxifen. Journal of clinical oncology : official journal of the American 
Society of Clinical Oncology. 2005;23(13):2980 -7. doi:  10.1200/JCO.2005.06.064. PubMed PMID: 
15860853.  
13. Lee O, Page K, Ivancic D, Helenowski I, Parini V, Sullivan ME, Margenthaler JA, Chatterton RT, Jr., 
Jovanovic B, Dunn BK, Heckman -Stoddard BM, Foster K, Muzzio M, Shklovskaya J, Skripkauskas S, 
Kulesza P , Green D, Hansen NM, Bethke KP, Jeruss JS, Bergan R, Khan SA. A randomized phase II 
presurgical trial of transdermal 4 -hydroxytamoxifen gel versus oral tamoxifen in women with ductal 
carcinoma in situ of the breast. Clin Cancer Res. 2014;20(14):3672 -82. d oi: 10.1158/1078 -0432.CCR -13-
3045. PubMed PMID: 25028506; PMCID: PMC4101910.  
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –43– 
08/31/2016   APPENDIX A  
Performance Status Criteria  
 
ECOG Performance Status Scale  
Grade  Descriptions  
0 Normal activity. Fully active, able to carry 
on all pre -disease performance without 
restriction.  
1 Symptoms, but ambulatory. Restricted in 
physically strenuous activity, but 
ambulatory and able to carry out work of a 
light or sedentary nature ( e.g., light 
housework, office work).  
2 In bed <50% of the time. Ambulatory and 
capable of all self -care, but unable to carry 
out any work activities. Up and about more 
than 50% of waking hours.  
3 In bed >50% of the time. Capable of only 
limited self -care, confined to bed or chair 
more than 50% of waking hours.  
4 100% bedridden. Completely disabled. 
Cannot carry on any self -care. Totally 
confined to bed or chair.  
5 Dead.  
 
Karnofsky Performance Scale  
Percent  Description  
100 Normal, no complaints, no evidence of 
disease.  
90 Able to carry on normal activity; minor 
signs or symptoms of disease.  
80 Normal activity with effort; some signs 
or symptoms of disease.  
70 Cares for self, unable to carry on normal 
activity or to do active work.  
60 Requires occasional assistance, but is 
able to care for most of his/her needs.  
50 Requires considerable assistance and 
frequent medical care.  
40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospitalization 
indicated. Death not imminent.  
20 Very sick, hospitalization indicated. 
Death not imminent.  
10 Moribund, fatal processes progressing 
rapidly.  
0 Dead.  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –44– 
08/31/2016   Appendix B  
 
GEL APPLICATION INSTRUCTIONS  
 
1. Flammable: do not apply near fire, flame or heat, or while smoking  
 
2. Apply the gel to your breast after bathing, preferably in the morning and at approximately the same time each 
day. Apply approximately 30 minutes after bathing when breast is comple tely dry.  
 
3. To apply, remove the cap from the bottle. When you use the bottle for the first time, you must prime it by 
pressing the pump fully several times until gel is dispensed (point the spout toward a sink or wastebasket and 
do not use the first dos e, which may be incorrect).  
 
4. Once the bottle is primed, hold it in one hand and place the palm of your other hand under the pump to catch 
the gel. Be sure to press down completely on the pump and release it completely to dispense one dose of gel.  
 
5. Apply one dose of gel to one breast (dosage is indicated on the bottle label). Do not apply more or less than 
one dose to the breast. If you are assigned to the 20mg dose level (which requires two (2) pumps ), be sure to 
release the pump completely between both actuations  (pumps) . Application of gel will always be to only one 
breast and the same breast each time. Do not alternate doses between breasts.  
 
6. If you accidentally pump more than is needed, please discard this dose and try agai n to get the correct dose. 
If you do discard pumped doses, please record this on your Gel D iary.  
 
7. Spread the gel evenly over the upper outer and upper inner quadrant of your breast, without rubbing. Start 
from above the areola and spread outwards to be low the clavicle and  up to the midsternal edge  which is the 
midline of your chest . Avoid spreading the gel in the nipple and areola area of the breast.  Avoid spreading the 
gel below the nipple or underneath the breast.  Please see diagram below.  
 
 
 
8. Wash  your hands immediately after applying the gel.  
 
9. Allow the gel on your breast to air dry for 2 minutes and then immediately cover with clothing (the gel is 
colorless and will not stain your clothing). Do not expose your bare breasts to sunlight or ultraviolet light 
(tanning beds) at any time while on the study.  
10. Do not apply any other cream, lotion or moisturizer to your breast immediately after application of the study 
drug.  
 
11. Do not wash your breast or immerse in water (bath, swim) for at l east 4 hours following application of the 

DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –45– 
08/31/2016   gel. If this is not possible, delay application of the gel that day until after immersion, and be sure to follow all 
the above instructions. If you regularly swim in the morning, it is better to apply the gel after wards, after your 
shower.  
 
12. After use, replace the cap on the bottle.  
 
RECOMMENDATIONS:  
 
1. Be sure to apply after bathing or showering, each day during the study and preferably in the morning.  
 
2. You may use CeraVe  moisturizing cream , a moisturizer that will be supplied to you, to apply to the same 
breast that you are applying the study gel. CeraVe  moisturizing cream can be used in the evening or at least 4 
hours after study gel application so it will not interfere with absorption . CeraVe  moisturizing cream can be 
applied daily to help with any skin redness.  
 
3. If you forget to apply a dose, do not double the dose to “catch up”.   
 
If you are applying the gel daily :  If your next dose is scheduled within the next 12 hours, it is best just to wait; 
if it is more than 12 hours until your next dose, apply the dose you missed and resume your normal dosing after 
that.  
 
If you are applying the gel every other day : If your next dose is scheduled within the next 2 4 hours, it is best 
just to wait; if it is more than 24 hours until your next dose, apply the dose you missed and resume your normal 
dosing after that.  
 
4. For the duration of the study, avoid contact betwe en the application area and the skin of other individuals 
(i.e. your child, your sexual partner, or other persons). If necessary, skin contact is allowable after the breast 
has been washed. As noted above, you must wait at least 4 hours following applicati on before washing the 
application area, otherwise, delay application until after washing and contact.  
5.  Avoid using sprays containing DEET (i.e. bug spray) to the treated area and limit vitamin A intake to <5000 
IU per day.  
 
6. Do not ingest or swallow the gel. For external use only.  
 
7. Please note the first and last day of use on the bottle label.  
 
8. If the pump doesn’t come back up correctly or if there’s no gel delivered when you press down on the pump, 
notify your doctor immediately. A replacemen t bottle will be shipped to you.  
 
9. After the end of study treatment, be sure to take back to your doctor all the gel bottles you have been given 
(even if empty or not used). This is very important for the success of the study .  
 
10. If any ulcerations, blisters or open areas start please notify the research team the next day for guidance.  
 
STORAGE INSTRUCTIONS:  
 
1. Keep your gel bottles in a cool room temperature - 59°F to 77°F .  
 
2. Keep the gel bottles out of the reach of children.   
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –46– 
08/31/2016   APPENDIX C  
 
Bexarotene Gel  Diaries  
 
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –47– 
08/31/2016    
Bexarotene Gel  Diary [ IRB Protocol #:                     ] 
 
Group 1  
 
PID: __ __ __ __ __ __ __ __ __ __  
 
Amount of Agent Provided: Number of Canisters ______  
 
Total Daily Dose: 10mg applied to one breast, every other day  
 
Pump actuations: Push the Pump 1 time  
 
Breast to Apply Gel: Right  OR Left 
 
Number of Canisters Returned: ________  
 
Visit#: ______  
 
 
INSTRUCTIONS:  
 
1. Complete the diary daily.   
 
2. If you miss an application, d o not take an extra application to “make up” for the missed application.   
 
If your next dose is scheduled within the next 24 hours, it is best just to wait; if it is more than 24 hours 
until your next dose,  apply the dose you missed and resume your normal dosing after that.  
 
3. If you accidentally pump more than is needed for one breast, please discard this dose and try again to 
get correct dose. If you do discard pumped doses, please record this on your Gel D iary.   
 
4. Do not discard the gel canister.  Bring the canister and this diary to your next appointment.  
 
5. Store the study gel at home at room temperature and avoid extreme heat or cold during transportation 
from the clinic to home.  
 
6. If you experience any concerning side effects  or changes in the texture of your skin (e.g ., skin feels like 
sandpaper) ,  call ________________________ (insert name of Study Coordinator or Study Nurse ) at 
__________________ (insert telephone number) or the study doctor, Dr. Parijatham Thomas at 713 -
745-8040 for guidance.  
 
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –48– 
08/31/2016   Bexarotene  Gel Diary  Group 1  Continued  
 
Please Bring this Sheet  and Empty Canister  to Your Next Visit  
 
Day Date  R or L Breast , 
OR Did not apply  Initials  Did you experience any symptoms, if 
“Yes” list below  
 
List # of discarded pumps of gel  here Week 1  
Apply 1 pump to the breast every 
other day  1  □R              □L  
□Did not apply    
2  □R             □L  
□Did not apply    
3  □R              □L  
□Did not apply    
4  □R              □L  
□Did not apply    
5  □R              □L  
□Did not apply    
6  □R              □L  
□Did not apply    
7  □R              □L  
□Did not apply    Week 2  
Apply 1 pump to the breast every 
other day  8  □R              □L  
□Did not apply    
9  □R              □L  
□Did not apply    
10  □R              □L  
□Did not apply    
11  □R              □L  
□Did not apply    
12  □R              □L  
□Did not apply    
13  □R              □L  
□Did not apply    
14  □R              □L  
□Did not apply    Week 3  
Apply 1 pump to the breast every 
other day  15  □R              □L  
□Did not apply    
16  □R              □L  
□Did not apply    
17  □R              □L  
□Did not apply    
18  □R              □L  
□Did not apply    
19  □R              □L 
□Did not apply    
20  □R              □L  
□Did not apply    
21  □R              □L  
□Did not apply    
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –49– 
08/31/2016    
 
 
 
Participant ’s Signature: _______________________________________  Date: ___________________  
 
Reviewer’s Signature: ________________________________________  Date: ___________________  
 
 
Comments: 
________________________________________________________________________________________ ______
______________________________________________________________________________ ________________
______________________________________________________________________________________________
______________________________________________________________  
 
   Day Date  R or L Breast ,  
OR Did not apply  Initials  Did you experience any symptoms, if 
“Yes” list below  
 
List # of discarded pumps of gel  here Week 4  
Apply 1 pump to the breast every other 
day 22  □R              □L  
□Did not apply  
   
23  □R              □L  
□Did not apply    
24  □R              □L  
□Did not apply    
25  □R              □L  
□Did not apply    
26  □R              □L  
□Did not apply    
27  □R              □L  
□Did not apply    
28  □R              □L  
□Did not apply     29  □R              □L  
□Did not apply    
30  □R              □L  
□Did not apply    
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –50– 
08/31/2016   Bexarotene Gel  Diary [ IRB Protocol #:                     ] 
 
Group 2  
 
PID: __ __ __ __ __ __ __ __ __ __  
 
Amount of Agent Provided: Number of Canisters ______  
 
Total Daily Dose:  
 
Week 1: 10mg applied to one breast, every other day   
Push the Pump 1 time 
 
Weeks 2 -4: 10mg applied to one breast, every day  
Push the Pump 1 time  
 
Breast to Apply Gel: Right  OR Left 
 
Number of Canisters Returned: ________  
 
Visit#: ______  
 
 
INSTRUCTIONS:  
 
1. Complete the diary daily.   
 
2. If you miss an application, do  not take an extra application to “make up” for the missed application.   
 
If you are applying the gel daily :  If your next dose is scheduled within the next 12 hours, it is best just 
to wait; if it is more than 12 hours until your next dose, apply the dos e you missed and resume your 
normal dosing after that.  
 
If you are applying the gel every other day : If your next dose is scheduled within the next 24 hours, it 
is best just to wait; if it is more than 24 hours until your next dose, apply the dose you mis sed and 
resume your normal dosing after that.  
 
3. If you accidentally pump more than is needed for one breast, please discard this dose and try again to 
get correct dose. If you do discard pumped doses, please record this on your Gel D iary.   
 
4. Do not discard  the gel canister.  Bring the canister and this diary to your next appointment.  
 
5. Store the study gel at home at room temperature and avoid extreme heat or cold during transportation 
from the clinic to home.  
 
6. If you experience any concerning side effects or  changes in the texture of your skin (e.g., skin feels like 
sandpaper),  call ________________________ (insert name of Study Coordinator or Study Nurse ) at 
__________________ (insert telephone number) or the study doctor, Dr. Parijatham Thomas at 713 -
745-8040 for guidance. .   
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –51– 
08/31/2016   Bexarotene  Gel Diary Group 2 Continued  
Please Bring this Sheet and Empty Canister to Your Next Visit  
 
   
Day Date  R or L Breast,  OR 
Did not apply  Initials  Did you experience any symptoms, if 
“Yes” list below  
 
List # of discarded pumps of gel  here Week 1  
Apply 1 pump to the breast every 
other day  1  □R              □L  
□Did not apply    
2  □R              □L  
□Did not apply    
3  □R              □L  
□Did not apply    
4  □R              □L 
□Did not apply    
5  □R              □L  
□Did not apply    
6  □R              □L  
□Did not apply    
7  □R              □L  
□Did not apply    Week 2  
Apply 1 pump to the breast every day  
8  □R              □L  
□Did not apply    
9  □R              □L 
□Did not apply    
10  □R              □L  
□Did not apply    
11  □R              □L  
□Did not apply    
12  □R              □L  
□Did not apply    
13  □R              □L  
□Did not apply    
14  □R              □L  
□Did not apply    Week 3  
Apply 1 pump to the breast every day  
15  □R              □L  
□Did not apply    
16  □R              □L  
□Did not apply    
17  □R              □L  
□Did not apply    
18  □R              □L  
□Did not apply    
19  □R              □L  
□Did not apply    
20  □R              □L  
□Did not apply    
21  □R              □L  
□Did not apply    
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –52– 
08/31/2016    
 
 
Participant’s Signature: _______________________________________  Date: ___________________  
 
Reviewer’s Signature: ________________________________________  Date: ___________________  
 
 
Comments: 
______________________________________________________________________________________________
___________________________________________________________________________________ ___________
______________________________________________________________________________________________
______________________________________________________________  
 
 
   
Day Date  R or L Breast , OR  
Did not apply  Initials  Did you experience any symptoms, if 
“Yes” list below  
 
List # of discarded pumps of gel here Week 4  
Apply 1 pump to the breast every day  
22  □R              □L  
□Did not apply    
23  □R              □L  
□Did not apply    
24  □R              □L  
□Did not apply    
25  □R              □L  
□Did not apply    
26  □R              □L  
□Did not apply    
27  □R              □L  
□Did not apply    
28  □R              □L 
□Did not apply     29  □R              □L  
□Did not apply    
30  □R              □L  
□Did not apply    
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –53– 
08/31/2016   Bexarotene Gel  Diary [ IRB Protocol #:                     ] 
 
Group 3  
 
PID: __ __ __ __ __ __ __ __ __ __  
 
Amount of Agent Provided: Number of Canisters ______  
 
Total Daily Dose:  
 
Week 1: 10mg applied to one breast, every other day   
Push the Pump 1 time  
 
Week 2: 10mg applied to one breast, every day  
Push the Pump 1 time 
 
Weeks 3 -4: 20mg applied to one breast, every day  
Push the Pump 2 times  
 
Breast to Apply Gel: Right  OR Left 
 
Number of Canisters Returned: ________  
 
Visit#: ______  
 
INSTRUCTIONS:  
 
1. Complete the diary daily.   
 
2. If you miss an application, do  not take an extra application to “make up” for the missed application.   
 
If you are applying the gel daily :  If your next dose is scheduled within the next 12 hours, it is best just to 
wait; if it is more than 12 hours until your next dose, apply the dose you missed and resume your normal 
dosing after that.  
 
If you are applying the gel every other day : If your  next dose is scheduled within the next 24 hours, it is 
best just to wait; if it is more than 24 hours until your next dose, apply the dose you missed and resume 
your normal dosing after that.  
 
3. If you accidentally pump more than is needed for one breast, please discard this dose and try again to get 
correct dose. If you do discard pumped doses, please record this on your Gel D iary.   
 
4. Do not discard the gel canister s.  Bring the canister s and thi s diary to your next appointment.  
 
5. Store the study gel at home at room temperature and avoid extreme heat or cold during transportation from 
the clinic to home.  
 
6. If you experience any concerning side effects or changes in the texture of your skin (e.g., sk in feels like 
sandpaper),  call ________________________ (insert name of Study Coordinator or Study Nurse ) at 
__________________ (insert telephone number) or the study doctor, Dr. Parijatham Thomas at 713 -745-
8040 for guidance.  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –54– 
08/31/2016    
Bexarotene  Gel Diary  Group 3  Continued  
 
Please Bring this Sheet and Empty Canister s to Your Next Visit  
 
 
 
   
Day Date  R or L 
Breast  Initials  # of pump s Did you experience any 
symptoms, if “Yes” list below  
 
List # of discarded doses here  Week 1  
Apply 1 pump to the breast 
every other day  1    ____     or   □Did not apply   
2    ____     or   □Did not apply   
3    ____     or   □Did not apply   
4    ____     or   □Did not apply   
5    ____     or   □Did not apply   
6    ____     or   □Did not apply   
7    ____     or   □Did not apply   Week 2  
Apply 1 pump to the breast 
every day  8    ____     or   □Did not apply   
9    ____     or   □Did not apply   
10    ____     or   □Did not apply   
11    ____     or   □Did not apply   
12    ____     or   □Did not apply   
13    ____     or   □Did not apply   
14    ____     or   □Did not apply   Week 3  
Apply 2 pump s to the breast 
every day  15    ____     or   □Did not apply   
16    ____     or   □Did not apply   
17    ____     or   □Did not apply   
18    ____     or   □Did not apply   
19    ____     or   □Did not apply   
20    ____     or   □Did not apply   
21    ____     or   □Did not apply   
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –55– 
08/31/2016    
 
 
Participant’s Signature: _______________________________________  Date: ___________________  
 
Reviewer’s Signature: ________________________________________  Date: ___________________  
 
 
Comments: 
______________________________________________________________________________________________
______________________________________________________________________________________________
____________________________________________________________________ __________________________
______________________________________________________________  
 
   
Day Date  R or L 
Breast  Initials  # of pump s Did you experience any 
symptoms, if “Yes” list below  
 
List # of discarded doses 
here  Week 4  
Apply 2 pumps to the breast 
every day  22    ____     or   □Did not apply   
23    ____     or   □Did not apply   
24    _____     or   □Did not apply   
25    _____     or   □Did not apply   
26    _____     or   □Did not apply   
27    _____     or   □Did not apply   
28    _____     or   □Did not apply    29    _____     or   □Did not apply   
30    _____     or   □Did not apply   
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –56– 
08/31/2016    
Bexarotene Gel  Diary [ IRB Protocol #:                     ] 
 
Dose Expansion Group  
 
PID: __ __ __ __ __ __ __ __ __ __  
 
Amount of Agent Provided: Number of Canisters ______  
 
Total Daily Dose: 10mg applied to one breast, every other day  
 
Pump actuations: Push the Pump 1 time  
 
Breast to Apply Gel: Right  OR Left 
 
Number of Canisters Returned: ________  
 
Visit#: ______  
 
 
INSTRUCTIONS:  
 
1. Complete the diary daily.   
 
2. If you miss an application, d o not take an extra application to “make up” for the missed application.   
 
If your next dose is scheduled within the next 24 hours, it is best just to wait; if it is more than 24 hours 
until your next dose, apply the dose you missed and resume your normal dosing after that.  
 
3. If you accidentally pump more than is needed for one b reast, please discard this dose and try again to 
get correct dose. If you do discard pumped doses, please record this on your Gel Diary .   
 
4. Do not discard the gel canister.  Bring the canister and this diary to your next appointment.  
 
5. Store the study gel a t home at room temperature and avoid extreme heat or cold during transportation 
from the clinic to home.  
 
6. If you experience any concerning side effects or changes in the texture of your skin (e.g., skin feels like 
sandpaper),  call ________________________ (insert name of Study Coordinator or Study Nurse ) at 
__________________ (insert telephone number) or the study doctor, Dr. Parijatham Thomas at 713 -
745-8040 for guidance.  
 
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –57– 
08/31/2016   Bexarotene  Gel Diary : Dose Expansion Group  (Continued ) 
 
Please Bring this Sheet and Empty Canister to Your Next Visit  
 
Day Date  R or L Breast, 
OR Did not apply  Initials  Did you experience any symptoms, if 
“Yes” list below  
 
List # of discarded pumps of gel  here Week 1  
Apply 1 pump to the breast every 
other day  1  □R              □L 
□Did not apply    
2  □R             □L  
□Did not apply    
3  □R              □L  
□Did not apply    
4  □R              □L  
□Did not apply    
5  □R              □L  
□Did not apply    
6  □R              □L  
□Did not apply    
7  □R              □L  
□Did not apply    Week 2  
Apply 1 pump to the breast every 
other day  8  □R              □L  
□Did not apply    
9  □R              □L  
□Did not apply    
10  □R              □L  
□Did not apply    
11  □R              □L  
□Did not apply    
12  □R              □L 
□Did not apply    
13  □R              □L  
□Did not apply    
14  □R              □L  
□Did not apply    Week 3  
Apply 1 pump to the breast every 
other day  15  □R              □L  
□Did not apply    
16  □R              □L  
□Did not apply    
17  □R              □L 
□Did not apply    
18  □R              □L  
□Did not apply    
19  □R              □L  
□Did not apply    
20  □R              □L  
□Did not apply    
21  □R              □L  
□Did not apply    
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –58– 
08/31/2016    
 
 
 
Participant’s Signature: _______________________________________  Date: ___________________  
 
Reviewer’s Signature: ________________________________________  Date: ___________________  
 
 
Comments: 
______________________________________________________________________________________________
______________________________________________________________________________________________
____________________________________________________________________ __________________________
______________________________________________________________  
 
 
 
   Day Date  R or L Breast,  
OR Did not apply  Initials  Did you experience any symptoms, if 
“Yes” list below  
 
List # of discarded pumps of gel  here Week 4  
Apply 1 pump to the breast every other 
day 22  □R              □L  
□Did not apply  
   
23  □R              □L  
□Did not apply    
24  □R              □L  
□Did not apply    
25  □R              □L  
□Did not apply    
26  □R              □L  
□Did not apply    
27  □R              □L  
□Did not apply    
28  □R              □L  
□Did not apply     29  □R              □L  
□Did not apply    
30  □R              □L  
□Did not apply    
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –59– 
08/31/2016   APPENDIX D 
 
Alcohol and Tobacco Use Assessment Questionnaires – Baseline  
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –60– 
08/31/2016   ALCOHOL ASSESSMENT – BASELINE  
 
REGISTERING INSTITUTION  
 
_________________________  PARTICIPANT ID  
 
_________________  VISIT TYPE  
 
________________  VISIT DATE  
(MM/DD/YYYY)  
___ ___ / ___ ___ / ___ ___ ___ ___  
 
Instructions:  
For the following questions about drinking alcoholic beverages, a drink means a 12 oz. beer, a 5 oz. 
glass of wine, or one and a half ounces of liquor.  
 
1. In your entire life, have you had at least 12 drinks of any kind of alcoholic beverage?  
 Yes 
 No (End)  
 Refused (End)  
 Don’t know /Not sure 
 
2. In the past 12 months, on average, how often did you drink any type of alcoholic beverage?  
 
________ (Enter the number of days you drank based on the timeframe checked below.  Enter 0 if you 
never drank and skip to Question 6.)   
 Week  
 Month  
 Year  
 Refused  
 Don’t know /Not sure  
 
3. In the past 12 months, on those days that you drank alcoholic beverages, on average, how many drinks   
did you have per day?  
________ (Enter the average number of drinks per d ay) 
 
 Refused  
 Don’t know /Not sure  
 
4. In the past 12 months, on how many days did you have 5 or more drinks of any alcoholic beverage?  
 
_________ (Enter the number of days you had 5 or more drinks, or enter 0 if none.)  
 Refused  
 Don’t know /Not sure  
 
5. Was there ever a time or times in your life when you drank 5 or more drinks of any kind of alcoholic 
beverage almost every day?  
 Yes 
 No  
 Refused  
 Don’t know /Not sure  
 
 
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –61– 
08/31/2016    
6. If you do not currently drink alcoholic beverages, but did in the past, how long has it been since  
you last drank regularly?  
 
 Within the past month (0 to 1 month ago)  
 Between 1 and 3 months (1 to 3 months ago)  
 Between 3 and 6 months (3 to 6 months ago)  
 Between 6 and 12 months (6 to 12 months ago)  
 Between 1 and 5 years (1 to 5 years ago)  
 Between 5 and 15 years (5 to 15 years ago)  
 More than 15 years ago  
 Don’t know/Not sure  
 Never drank regularly  
 
7. At the heaviest point, either now or in the past, on the days when you drank, about how many drinks did 
you drink a day on the average?  
 
__________ (Enter the number of drinks a day)  
  
 Refused  
 Don’t know/Not sure  
 
8. How many years have you been drinking (or did drink) regularly?  
 
______ years  
 
 Refused  
 Don’t know/Not sure  
 
9. At what age did you begin drinking regularly?  
 
______ years of age   
 
 Refused  
 Don’t know/Not sure  
 
10. What type(s) of alcohol do you drink? (Mark ALL that apply)  
 
 Wine  
 Liquor  
 Beer 
 Wine cooler  
 
Signature  of Individual Completing This Form ___________________   Date  __ __ / __ __ / __ __ __ _ _ 
 (MM/DD/YYYY)  
Name of Individual Completing This Form  (please print) ______________________________________  
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –62– 
08/31/2016   TOBACCO ASSESSMENT – BASELINE  
 
REGISTERING INSTITUTION  
 
_________________________  PARTICIPANT ID  
 
_________________  VISIT TYPE  
 
________________  VISIT DATE  
(MM/DD/YYYY)  
___ ___ / ___ ___ / ___ ___ ___ ___  
 
 
Section A. Basic Cigarette Use Information  
 
1. Have you smoked at least 100 cigarettes (5 packs = 100 cigarettes) in your entire life?  
 
Yes   
 No → Skip to Section B  
 Don’t kno w/Not sure → Skip to Section B  
 
2. How old were you when you first smoked a cigarette (even one or two puffs)?  
 
_______ Years old   
 
3. How old were you when you first began smoking cigarettes regularly?   
 
_______ Years old   
  Check here if you have never smoked cigarettes regularly.  
 
4. How many total years have you smoked (or did you smoke) cigarettes? Do not count any time you may 
have stayed off cigarettes.  
 
______ Years (If you smoked less than one year, write “1.”)   
 
5. On  average when you have smoked, about how many cigarettes do you (or did you) smoke a day?  (A pack 
usually has 20 cigarettes in it).   
 
_____ Number of cigarettes per day  
 
6. Do you NOW  smoke cigarettes?  
 
 Everyday  
 Some days  
 Not at all → Skip t o question 8  
 
7.  How soon after you wake up do you smoke your first cigarette?  
 
  Within 30 minutes  
  After 30 minutes  
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –63– 
08/31/2016    
8. How long has it been since you last smoked a cigarette (even one or two puffs)?  
 
First check which one of the following choices applies to you. Then, if applicable, write a number on the 
line 
for how many days, weeks, months, or years it has been since your last cigarette.  
 
 I smoked a cigarette today (at least one puff)  
 1-7 days → Number of days since last cigarette  ________  
 Less than 1 month → Number of weeks since last cigarette  _________  
 Less than 1 year → Number of months since last cigarette  __________  
 More than 1 year → Number of years since last cigarette  ___________  
 Don’t know/Don’t remember  
 
Section B. Use of Other Forms of Tobacco  
 
9.  Have  you ever used other forms of tobacco, not including cigarettes?  
  
 Yes  
 No → Skip to Section C  
 
10. How often do you/did you use other forms of tobacco?  
 
 Every day → Number of times per day  ________  
 Some days → Number of days _______ per   Week   Month  Year  
 
11. Which of the following products have you ever used regularly?  
 Check all that apply  
 
 Cigarettes  
 E-cigarettes or other electronic nicotine delivery system  
 Traditional cigars, cigarillos or filtered cigars  
 Pipes  
 Hookah  
 Clove cigarettes or kreteks  
 Bidis  
 Smokeless tobacco, like dip, chew, or snuff  
 Snus  
 Paan with tobacco, gutka, zarda, khaini  
 Other, Please specify:___________________________  
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –64– 
08/31/2016   12. If you do not currently use other forms of tobacco, but did in the past, how long has it been since you last 
used other forms of tobacco regularly?  
 
 Within the past month (0 to 1 month ago)  
 Between 1 and 3 months (1 to 3 months ago)  
 Between 3 and 6 months (3 to 6 months ago)  
 Between 6 and 12 months (6 to 12 months ago)  
 Between 1 and 5 years (1 to 5 years ago)  
 Between 5 and 15 years (5 to 15 years ago)  
 More than 15 years ago  
 Don’t know/Not sure  
 Never use d other forms of tobacco regularly  
 
Section C. Second -Hand Smoke Exposure  
 
13. Are you currently living with a smoker?   
 
Yes  
 No  
 
14. In the past 30 days, have you lived  in a place where other people smoked cigarettes indoors?  
 
Yes  
 No  
 
15. In the past 30 days, have you worked  in a place where other people smoked cigarettes indoors?  
 
Yes  
 No  
 
16. Thinking of all your childhood and adult years, have you ever lived  in a place where oth er people smoked 
cigarettes indoors?  
 
 Yes In total, for about how many years?_______ If less than 1, write “1.”   
 No  
 
17. Thinking of all the years you ha ve worked,  have you ever worked  in a place where other people smoked 
cigarettes indoors?    
 
Yes → In total, for about how many years?_______ If less than 1, write “1.”    
 No 
 
Signature  of Individual Completing This Form ___________________   Date  __ __ / __ __ / __ __ __ __  
 (MM/DD/YYYY)  
Name of Individual Completing This Form  (please print) ______________________________________  
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –65– 
08/31/2016   APPENDIX E 
 
Alcohol and Tobacco Use Assessment Questionnaires – Follow Up  
 
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –66– 
08/31/2016   ALCOHOL ASSESSMENT – FOLLOW UP  
 
REGISTERING INSTITUTION  
 
_________________________  PARTICIPANT ID  
 
_________________  VISIT TYPE  
 
________________  VISIT DATE  
(MM/DD/YYYY)  
___ ___ / ___ ___ / ___ ___ ___ ___  
 
Instructions:  
 
For the following questions about drinking alcoholic beverages, a drink means a 12 oz. beer, a 5 oz. 
glass of wine, or one and a half ounces of liquor.  
 
1. During the past 30 days, did you drink any alcoholic beverages?  
 
 Yes 
 No (End)  
 Refused (End)  
 Don’t know/Not sure  
 
2. During the past 30 days, how many days per week or per month did you drink any alcoholic beverages, on 
the average?  
 
________ (Enter number of days you drank based on the timeframe checked below.  Enter 0 if you did 
not drink.)  
 
 Week  
 Month  
 Refused  
 Don’t know /Not sure  
 
3. On the days when you drank, on average, about how many drinks did you have?   
 
________ (Enter the average number of drinks you had per day.)  
 
 Refused  
 Don’t know /Not sure  
 
4. In the past 30 days, on how many days did you have 5 or more drinks per day?  
 
______ _______Number of times  
 
 None  
 Do not know/Not sure  
 
 
Signature  of Individual Completing This Form ___________________   Date  __ __ / __ __ / __ __ __ __  
 (MM/DD/YYYY)  
Name of Individual Completing This Form  (please print) ______________________________________  
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –67– 
08/31/2016   TOBACCO ASSESSMENT – FOLLOW UP  
 
REGISTERING INSTITUTION  
 
_________________________  PARTICIPANT ID  
 
_________________  VISIT TYPE  
 
________________  VISIT DATE  
(MM/DD/YYYY)  
___ ___ / ___ ___ / ___ ___ ___ ___  
 
1. Do you NOW  smoke cigarettes?  
 
 Everyday  
 Some days  
 Not at all → Skip to Question 3.  
 
2. On average, when you smoked, about how many cigarettes do you (or did you) smoke a day? (A pack 
usually has 20 cigarettes in it).     
 
_____ Number of cigarettes per day  
 
3. How long has it been since you last smoked a cigarette (eve n one or two puffs)?    
 
First check which one of the following choices applies to you. Then, if applicable, write a number on the 
line  
for how many days, weeks, months, or years it has been since your last cigarette.  
 
 I smoked a cigarette today (at least one puff)  
 1-7 days → Number of days since last cigarette ________  
 Less than 1 month → Number of weeks since last cigarette _________  
 Less than 1 year → Number of months since last cigarette ______ ____  
 More than 1 year → Number of years since last cigarette ___________  
 Don’t know/Don’t remember  
 
4. Since your last visit, have you used other forms of tobacco, not including cigarettes?  
 
 Yes 
  No (End) 
 
5. How often do you/did you use other forms of tobacco?  
 
 Every day → Number of times per day ________  
 Some days → Number of days _______ per   Week   Month  Year  
 
 
 
 
 
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –68– 
08/31/2016   6. Since your last visit, which of the following products have you used?  Check all that apply  
 
 Cigarettes  
 E-cigarettes or other electronic nicotine delivery system  
 Traditional cigars, cigarillos or filtered cigars  
 Pipes  
 Waterpipe  
 Hookah  
 Clove cigarettes or kreteks  
 Bidis  
 Smokeless tobacco, like dip, chew, or snuff  
 Snus  
 Paan with tobacco, gutka, zarda, khaini  
 Other, Specify____________________________________________________________________  
 
7. If you do not currently use other forms of tobacco , but did in the past, how long has it been since you last 
used other forms of tobacco regularly?  
 
 Within the past month (0 to 1 month ago)  
 Between 1 and 3 months (1 to 3 months ago)  
 Between 3 and 6 months (3 to 6 months ago)  
 Between 6 and 12 months (6 to 12 months ago)  
 Between 1 and 5 years (1 to 5 years ago)  
 Between 5 and 15 years (5 to 15 years ago)  
 More than 15 years ago  
 Don’t know/Not sure  
 Never used other forms of tobacco regularly  
 
The following instructions pertain to questions 8 - 10.  During each of the following time frames, please 
indicate whether you smoked cigarettes every day, some days, or not at all.  
 
8.  During study treatment  
 
 Smoked every day  
 Smoked some days  
 Did not smoke at all  
 Don’t know/not sure  
 Not applicable  
 
9.  After the end of study treatment  
  
 Smoked every day  
 Smoked some days  
 Did not smoke at all  
 Don’t know/not sure  
 Not applicable (I have not completed the study treatment)  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –69– 
08/31/2016     
 
 
10.  Since your last visit to this clinic  
  
 Smoked every day  
 Smoked some days  
 Did not smoke at all  
 Don’t know/not sure  
 Not applicable (This is my first visit to this clinic)  
 
 
 
Signature  of Individual Completing This Form ___________________   Date  __ __ / __ __ / __ __ __ __  
 (MM/DD/YYYY)  
Name of Individual Completing This Form  (please print) ______________________________________  
 
 
 
 
 
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –70– 
08/31/2016   APPENDIX F 
 
Resources for tobacco and alcohol quitting  
 
 
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –71– 
08/31/2016   National and local resources to help with alcohol abuse and 
alcoholism  
NIAAA ’s online guide Treatment for Alcohol Problems: Finding and Getting Help  is written for 
individuals, and their family and friends, who are looking for options to address alcohol problems. It 
is intended as a resource to understand what treatment choices are available and what t o consider 
when selecting among them.  https://pubs.niaaa.nih.gov/publications/treatment/treatment.htm  
Other resources:  
National Institute on Alcohol Abuse and Alcoholism www.niaaa.nih.gov  
301–443–3860  
National Institute on Drug Abuse www.nida.nih.gov  
301–443–1124  
National Clearinghouse for Alcohol and Drug Information www.samhsa.gov  
1–800–729–6686  
Substance Abuse Treatment Facility Locator www.findtreatment.samhsa.gov  
1–800–662–HELP  
Alcoholics Anonymous (AA) www.aa.org  
212–870–3400 or check your local phone directory under “Alcoholism”  
Moderation Management www.moderation.org  
212–871–0974  
Secular Organizations for Sobriety www.sossobriety.org  
323–666–4295  
SMART Recovery www.smartrecovery.org  
440–951–5357  
Women for Sobriety www.womenforsobriety.org  
215–536–8026  
Al-Anon Family Groups www.al -anon.alateen.org  
1–888–425–2666 for meetings  
Adult Children of Alcoh olics  www.adultchildren.org  
310–534–1815    
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –72– 
08/31/2016   National and local resources to help with  quitting smoking  
NCI’s Smokefree.gov  offers science -driven tools, inform ation, and support that has helped smokers 
quit. You will find state and national resources, free materials, and quitting advice from NCI.  
Smokefree.gov was established by the Tobacco Control Resear ch Branch  of NCI, a component of 
the National Institutes of Health, in collaboration with the Centers for Disease Control and 
Prevention and other organizations.  
Publications available from the Smokefree.gov Web site include the following:  
• Clearing the Air: Quit Smoking Today  for smokers interested in quitting.  
• Clear Horizons  for smokers over age 50.  
• Forever Free™   for smokers who have recently quit.  
• Forever Free for Baby and Me™ , in English  and Spanish , for pregnant smokers who have 
recently quit.  
• Pathways to Freedom: Winning the Fight Against Tobacco  for African American smokers.  
NCI’s Smoking Quitline  at 1–877–44U–QUIT (1 –877–448–7848)  offers a wide range of services, 
including individualized counseling, printed information, referrals to other  resources, and recorded 
messages. Smoking cessation counselors are available to answer smoking -related questions in 
English or Spanish, Monday through Friday, 8:00 a.m. to 8:00 p.m., Eastern time. Smoking cessation 
counselors are also available through LiveHelp , an online instant messaging service. LiveHelp is 
available Monday through Friday, 8:00 a.m. to 11:00 p.m., Eastern time.  
Your state has a toll -free telephone quitline. Call 1–800–QUIT –NOW (1 –800–784–8669)  to get 
one-on-one help with quitting, support and coping strategies, and referrals to resources and local 
cessation programs. The toll -free number routes callers to state -run quitlines, which provide free 
cessation assistance and resource information to a ll tobacco users in the United States. This initiative 
was created by the Department of Health and Human Services . For more information about quitlines, 
speak to an e xpert  on the Smokefree.gov Web site.  
 
  
DCP Protocol Number  MDA2016 -08-02 
Protocol Version 14, Date d 4/27/2021 
 
DCP Protocol Template Version 8.5 –73– 
08/31/2016    
APPENDIX G  
 
Plain Language Guide for Assessing Skin Application AEs 
Utilize this guide for assessing Skin Application AEs during the Day 8 phone call and Day 15 and Day 28 
visits.  To assess skin toxicity please ask the participant non -leading questions such as “Have you noted any 
changes in the skin of your breast?”  If the participant reports yes, then utilize the plain language guide below 
to ask more probing questions as needed.  
 
1. Is your breast skin dry  from gel application? If yes, is it red or itchy?   
 
2. Do you have pain on your breast skin? If yes, how severe?  
 
3. Is your skin itchy from gel application? If yes, how severe? Are you taking any medicine for it?  
 
4. Do you have rash on your breast skin? If yes, how big is the affected area? Are you taking any 
medicine for it? Can you please send us a picture of your rash?  
 
5. Do you have hives on the breast skin where you have applied the gel? If yes, how big is the aff ected 
area? Are you taking any medicine for it?  
 
 